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Abstract  4 
  Antigen  presenting  cells  such  as  macrophages  and  dendritic  cells  play  an 
important role between the interface of the innate and adaptive immune responses. One 
property shared by dendritic cells and macrophages is that upon activation they secrete 
either pro- or anti-inflammatory cytokines dependent on the pathogen derived product 
and  the  T  cell  derived  signal  they  encounter.  The  panel  of  cytokines  they  produce 
determines the class of the adaptive immune response. 
Tpl-2  was  originally  described  as  a  proto-oncogene.  It  was  later  found  to 
function  as  a  Map-3  kinase  leading  to  phosphorylation  of  MEK  and  ERK.  Upon 
stimulation of dendritic cells and macrophages with Toll like receptor ligands (TLR) 
such as LPS and CpG, Tpl-2 phosphorylates MEK, which in turn phosphorylates ERK, 
leading to production of cytokines. 
In the Tpl-2 knockout mice, it has been shown that TNF production is decreased. 
We have confirmed this finding and shown that this is both at the transcriptional and 
post-transcription  level.  In  the  complete  absence  of  Tpl-2  we  have  shown  that 
production of the suppressive cytokine IL-10 is reduced in response to TLR stimulation 
in macrophages and dendritic cells. On the other hand, when macrophages and dendritic 
cells are stimulated with LPS or CpG in the absence of Tpl-2, production of IL-12 is 
increased. IFN-β is also upregulated in absence of Tpl-2. Tpl-2 can regulate IL-12 either 
directly via IL-10, but also independently of IL-10 via ERK. 
IL-10 is an important cytokine in regulating the immune response in order to 
inhibit  immune  pathology.  We  crossed  the  Tpl-2  knockout  with  an  IL-10  knockout 
mouse in order to investigate whether Tpl-2 regulates IL-12 and IFN-β in the complete 
absence of IL-10. These studies are currently in progress. Preliminary results however,   5 
show  that  the  Tpl-2/IL-10  double  knockout  develop  diarrhoea  and  colitis  around  8 
weeks  of  age,  leading  to  minimal  weight  gain  and  even  weight  loss  compared  to 
littermates. This is in contrast to the Tpl-2 knockout, which does not develop colitis and 
the IL-10 knockout, which only develops colitis at 4 months of age. These findings have 
important  implications  for  treatment  of  autoimmune  diseases  with  drugs  that  inhibit 
ERK, to inhibit TNF mediated pathology. 
The aim of this thesis was to investigate to role ERK has in regulating cytokine 
production in DC and macrophages. We used two different strategies to do this. Firstly 
we  pharmacologically  blocked  ERK  phosphorylation  with  an  inhibitor.  Secondly  we 
used genetically modified mice lacking Tpl-2.   6 
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Introduction  18 
 
1.1 Regulation of the immune response 
 
1.1.1  Cytokines in the innate and adaptive immune response. 
 
The immune system can be divided into the innate and the adaptive immune 
responses.  These  are  characterised  by  which  cell  types  are  activated.  The  innate 
responses  involve  macrophages,  dendritic  cells  (DC),  natural  killer  (NK)  cells  and 
neutrophils, and the adaptive responses involve B cells and T cells. The innate immune 
system is the first line of defence during infections. The adaptive immune response only 
comes into action at a later stage (Palucka and Banchereau 2002). 
The  cells  of  the  immune  system  have  very  specific  roles  to  play  during  an 
immune response. Innate immune cells can recognise pathogens through several surface 
receptors such as pattern recognition receptors and Toll-like receptors (TLR) (discussed 
in detail later). These receptors enable the cells to take up the antigen. This process leads 
to production of cytokines, which will activate more cells including those of the adaptive 
response. DC are very specialised cells (Palucka and Banchereau 2002; Steinman and 
Hemmi 2006). They will take up antigen, which they will present to T cells and thereby 
activate the adaptive immune response (Janeway and Medzhitov 2002).  
T  cells  of  the  adaptive  immune  system  can  be  further  subdivided  into  two 
groups,  comprising  CD4
+  T  cells  divided  into  T  helper  1  (Th1),  T  helper  2  (Th2) 
(O'Garra  1998),  CD25
+foxp3  regulatory  T  cells  (Treg)  (O'Garra  and  Vieira  2004; 
Sakaguchi 2005), T helper 17 (Th17) (Veldhoen et al. 2006); and CD8
+ cytotoxic T   19 
cells. The type of T cell that becomes activated depends on the signal received from the 
DC and on signals from co-stimulatory molecules, and whether the antigen is presented 
on class I (CD8) or class II (CD4) MHC molecules. Furthermore, DC produce IL-12 
upon interaction with a naïve CD4
+ T cell, will induce a Th1 response. Under certain 
conditions and in the absence of IFN-γ, CD4
+ T cells will be driven in a Th2 direction, 
which is dependent on IL-4 (O'Garra 1998). Th17 cells differentiate from CD4
+  naïve T 
cells in response to TGF-β and IL-6 and are expanded by IL-23 (Bettelli et al. 2006; 
Veldhoen et al. 2006). 
Th1 responses are characterised by production of IFN-γ and are responsible for 
eradication  of  intracellular  pathogens,  but  if  uncontrolled  can  cause  inflammatory 
pathologies (O'Garra 1998). Th2 responses are characterised by production of IL-4, IL-5 
and IL-13 and are responsible for eradication of nematodes but are also implicated in 
allergy (Sher and Coffman 1992; O'Garra 1998). Treg (CD25
+Foxp3) cells are important 
in  controlling  both  the  innate  and  adaptive  immune  system  (Sakaguchi  2005).  Their 
suppressive effects can in some cases be mediated by IL-10 and TGF-β, in order to 
downregulate an inflammatory response (O'Garra and Vieira 2004). It has been shown 
that Treg can inhibit T cell expansion and function in certain disease models (reviewed 
in (O'Garra et al. 2004). More recently a new T cell subset, Th17 was described. Th17 
cells  produce  the  inflammatory  cytokine  IL-17,  which  plays  a  part  in  autoimmune 
diseases (Cua et al. 2003). The differentiation into Th17 effector cells requires TGF-β 
production,  which  paradoxically  is  normally  associated  with  downregulation  of 
inflammatory immune responses (Veldhoen et al. 2006).   20 
The  cytokines  produced  during  an  immune  response  are  critical  in  order  to 
achieve complete eradication of the pathogen without causing damage to the host. Two 
cytokines responsible for downregulating the immune response are IL-10 and TGF-β. 
IL-10 is produced by a variety of cells including macrophages, DC, T cells and B cells 
(Moore et al. 2001). IL-10 works by inhibiting macrophage and DC function including 
their production of multiple proinflammatory cytokines such as TNF and IL-12. IL-12 
produced by DC can drive a Th1 response, which can be downregulated by various 
factors such as IL-10 and TGF-β (Moore et al. 2001). TGF-β works by inhibiting Th1 
and Th2 cell differentiation but also actively drives Th17 differentiation in the context of 
IL-6. IL-23 then expands committed Th17 effectors (Veldhoen and Stockinger 2006). 
IL-10 is a very important cytokine for immune regulation. The effects of IL-10 
have been studied in IL-10 deficient mice, which spontaneously develop colitis caused 
by high levels of TNF and IL-12 and also the Th1 response (Kuhn et al. 1993) and the 
recently described IL-23 (Hue et al. 2006; Kullberg et al. 2006). However, too much IL-
10 can lead to deactivation of macrophages and in an infection study with Toxoplasma 
gondii, it was shown that IL-10 inhibited parasite killing which led to an uncontrolled 
infection  (Gazzinelli  et  al.  1992).  However,  in  the  absence  of  IL-10,  infection  with 
Toxoplasma gondii led to more effective clearance of the parasite, but the mice died of 
uncontrolled immunopathology (Gazzinelli et al. 1992). 
IFN-γ, which is produced by Th1 cells, plays an important part in the immune 
response to intracellular pathogens (Novelli and Casanova 2004). In the absence of IFN-
γ,  an  individual  becomes  susceptible  to  infections  with  various  intracellular 
microorganisms (Novelli and Casanova 2004). It was recently shown that patients with   21 
defects in IFN-γ receptors were susceptible to infections with mycobacteria (Casanova 
and Abel 2002).  
Regulation of the balance of the immune response is very important, as too much 
of a Th1 response can cause autoimmune or inflammatory pathology but is required for 
effective eradication of pathogens. On the other hand, too much of a Th2 response can 
cause allergy, but is required for eradication of nematodes (Sher and Coffman 1992; 
O'Garra 1998). Th17 thus far have only been shown to affect the clearance of Klebsiella 
pneumoniae  (Happel  et  al.  2005)  and  if  dysregulated  cause  anti-inflammatory 
pathologies (Chen et al. 2006; Veldhoen and Stockinger 2006). In order to understand 
this  balance,  it  is  important  to  study  the  antigen  presenting  cells  particularly 
macrophages  and  DC,  which  are  responsible  for  communication  with  T  cells.  The 
cytokines  produced  by  DC  and  macrophages  may  determine  the  type  of  immune 
response elicited to pathogens (Banchereau and Steinman 1998).  
 
1.1.2  Dendritic cells as initiators of the immune response.   
 
Dendritic cells (DC) are described as professional antigen presenting cells (APC) 
and they function at the interface between innate and adaptive immune responses where 
they take up and process antigen for presentation to T cells (Banchereau and Steinman 
1998; Liu et al. 2001; Robinson and O'Garra 2002; Shortman and Liu 2002; Kapsenberg 
2003; Smits et al. 2004). 
DC are found in most tissues as immature cells unable to present antigen to T 
cells. Their role is to capture antigen they encounter. Upon antigen uptake, the DC will   22 
start to undergo maturation. The antigen will be processed in specialised MHC class II-
rich compartments, where the antigen is broken down for presentation of peptides on 
MHC class II molecules on the cell surface to CD4
+ T cells or MHC class I molecules to 
CD8
+ T cells (Banchereau and Steinman 1998). It has been suggested that DC become 
activated  to  secrete  either  pro-  or  anti-inflammatory  cytokines  dependent  on  the 
pathogen derived product and the T cell derived signal they encounter. Upon activation 
and maturation, DC start to migrate to the lymph nodes, where processed antigen is 
presented to T cells through interaction with MHC and costimulatory molecules. DC can 
drive the immune response in either a T helper 1 (Th1) or Th2 direction depending on a 
number of factors, including the cytokines produced in their microenvironment (O'Garra 
1998).  
Different subsets of DC have been identified (Liu et al. 2001; Shortman and Liu 
2002). These include the myeloid, plasmacytoid and splenic DC. Myeloid DC (CD11c
+ 
CD11b
+) can be generated directly in vitro from murine bone marrow by culturing in 
medium containing GM-CSF (Inaba et al. 1992). Upon appropriate stimulation with LPS 
or other ligands for pattern recognition receptors expressed on these cells (Medzhitov 
2001), myeloid DC produce IL-12, TNF and IL-10 (Boonstra et al. 2003). Although 
mouse DC expressing CD11c
+CD11b
+ can be isolated directly from the spleen, it is still 
unclear  how  these  or  other  so-called  “steady-state”  DC  relate  to  the  bone  marrow 
derived myeloid DC (Banchereau and Steinman 1998; Liu et al. 2001; Shortman and Liu 
2002). 
Murine  plasmacytoid  precursor  DC  (pDC)  (CD11c
dull  B220
+  GR1
+)  can  be 
obtained directly from the spleen and lymph nodes (Asselin-Paturel et al. 2001). Upon   23 
stimulation  with  virus, pDC  produce  large  amounts  of  IFN-α  (Asselin-Paturel  et  al. 
2001; Bjorck 2001; Nakano et al. 2001; Asselin-Paturel et al. 2003; Boonstra et al. 
2003). Plasmacytoid DC (pDC) (CD11c
+ CD11b
- B220
+) can also be generated from 
murine bone marrow by culturing with FLT3L instead of GM-CSF (Gilliet et al. 2002). 
FLT3L  generated pDC  produce large amounts of  IL-12, some TNF but no IL-10 in 
response to stimulation through TLR7 or TLR9 (Boonstra et al. 2003). 
 
1.1.3 Macrophages in the immune response. 
 
Macrophages belong to the group of innate immune cells. Their main functions 
are  to  detect,  ingest  by  phagocytosis  and  destroy  pathogens.  They  can  also  present 
antigen to T cells (Morrissette et al. 1999). Macrophages are highly phagocytic and are 
capable of ingesting pathogens as well as apoptotic cells. They have several surface 
receptors involved in innate immune recognition including toll-like receptors (described 
in  detail  below),  and  other  pattern  recognition  receptors  (PRR)  such  as  scavenger 
receptors, which they use to detect pathogens and accelerate them to produce cytokines 
(Taylor et al. 2005). 
  Activation  of  macrophages  can  occur  through  a  number  of  signals  such  as 
ligands for PRR and cytokines. One cytokine signal is IFN-γ produced by NK and T 
cells, which primes the macrophages for activation. Another cytokine signal is TNF, 
which is produced by macrophages and DC in response to many pathogens upon PRR 
and also engagement by T cells (Mosser 2003). Upon activation, macrophages migrate 
to the site of inflammation, where they start to degrade pathogens. Both resting and   24 
activated macrophages have an enhanced ability to phagocytose the pathogen, however, 
activated  macrophages  have  an  enhanced  ability  to  kill  and  degrade  intracellular 
microorganisms  (Mosser 2003).  
Macrophages  can  kill  pathogens  in  many  ways.  Some  of  these  include 
phagocytosis, release of antimicrobial peptides and reactive oxygen intermediates, or by 
activation of the complement system via the alternative pathway (Bogdan et al. 2000). 
One of the main defence mechanisms of macrophages is their ability to produce nitric 
oxide  (NO)  in  order  to  kill  pahogens.  Production  of  NO  is  only  induced  after 
macrophage activation with IFN-γ produced by Th1 and NK cells. It has been shown 
that  in  infection  with  many  intracellular  pathogens  such  as  Leishmania  major, 
macrophages produce NO to inhibit the replication of the parasite. NO deficient mice, 
showed  non-healing  lesions  in  response  to  Leishmania  major  infection.  (Celada  and 
Nathan 1994; Bogdan et al. 2000). 
Macrophages are very poor at presenting antigen to T cells, as compared to DC 
(Morrissette et al. 1999). However, they play an important role in innate immunity by 
killing pathogens. Macrophages can, however,  be very damaging to the host if their 
activation is not controlled due to the production of toxic radicals and inflammatory 
cytokines. Therefore it is very important that there  are mechanisms to  downregulate 
macrophage activation. Such regulation can be provided by other cells or even by the 
macrophage itself. It has been found that transforming growth factor-β (TGF-β) and IL-
10 are important in turning off activated macrophages (Bogdan et al. 1991; Fiorentino et 
al. 1991; Fiorentino et al. 1991; Gazzinelli et al. 1992). 
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1.1.4  Toll-like  receptors:  Pattern  recognition  receptors  expressed  by  DC  and 
macrophages. 
 
Toll  like  receptors  (TLRs)  are  conserved  PRR  that  recognise  patterns  on 
microbes (Martin et al. 2003; Takeda et al. 2003). TLRs were originally identified in 
Drosophila  Melanogaster  as  an  essential  receptor  for  dorso-ventral  development  in 
embryos (Hashimoto et al. 1988). It was later demonstrated that mutant flies lacking 
TLRs  were  highly  susceptible  to  fungal  infections  (Hoffmann  et  al.  1999).  TLRs 
comprise a family of type I transmembrane receptors characterised by an extracellular 
leucine-rich repeat domain and an intracellular Toll/IL-1 receptor domain (Medzhitov 
2001).  
To date, 11 TLR have been identified in mammals. The extracellular domain 
confers sensitivity for specific ligands. The conserved Toll/IL-1 receptor (TIR) domain 
couples  TLR  to  intracellular  signalling  pathways  by  recruiting  cytoplasmic  adaptor 
proteins  following  ligand  stimulation.  The  specific  ligands  for  each  receptor  are 
summarised in Table 1 and have been validated using TLR knockout animals (Hoshino 
et al. 1999; Takeuchi et al. 1999; Hemmi et al. 2000; Alexopoulou et al. 2001; Hayashi 
et al. 2001; Takeuchi et al. 2001; Hemmi et al. 2002; Takeuchi et al. 2002). 
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Toll-like receptor  Ligand  Origin 
TLR1  Triacyl lipopeptides  Bacteria 
TLR2 
Lipopeptides 
Peptidoglycan 
Zymosan 
Various pathogens 
Gram-positive bacteria 
Fungi 
TLR3  Double stranded RNA  Virus 
TLR4  Lipopolysaccharide 
Gram-negative 
bacteria 
TLR5  Flagellin  Bacteria 
TLR6 
Diacyl lipopeptides 
Zymosan 
Mycoplasma 
Fungi 
TLR7  Single-stranded RNA  Virus 
TLR8 
Imidazoquinoline 
Single-stranded RNA 
Synthetic compounds 
Virus 
TLR9 
CpG-containing non-
methylated DNA 
Bacteria 
Virus 
TLR10  Not determined  Not determined 
TLR11  Not determined  Uropathogenic bacteria 
 
 
 
  When  a  TLR  specific  ligand  interacts  with  its  appropriate  TLR,  a  signalling 
cascade is initiated and several adaptor proteins are recruited to the TIR domain of the 
TLR. All TLRs signal through MyD88, an adaptor protein, apart from TLR3, which 
utilises a MyD88 independent pathway through TRIF (discussed in more detail below) 
(Akira et al. 2003). Many of the TLRs also use several other adaptor proteins, and as a 
result of these signalling cascades, transcription of cytokines is initiated. We are mainly 
focussed on TLR4 and TLR9 for this thesis, which are described in detail below. 
Table 1. Summary of Toll-like receptors and their major ligands. Modified from 
(Akira and Takeda 2004). The TLR ligands we are working with are highlighted in 
bold.   27 
 
1.1.5 Differential TLR expression by DC and macrophages. 
   
TLRs are expressed in many cells of the immune system. These include; B cells, 
macrophages  and  DC.  Mouse  and  human  DC  subtypes  express  different  TLRs  and, 
therefore, respond to different microbial products (Kadowaki et al. 2001; Edwards et al. 
2002; Boonstra et al. 2003). TLR4 (LPS) is expressed by macrophages, mouse myeloid 
DC, human monocyte-derived DC, and human macrophages but not by pDC (Kadowaki 
et al. 2001; Boonstra et al. 2003). TLR9 (CpG) is expressed by both human pDC and 
human B cells.  In the mouse however, pDC, myeloid DC, splenic DC, B cells, and 
macrophages  express  TLR9  (Kadowaki  et  al.  2001;  Boonstra  et  al.  2003).  TLR2 
(lipopeptides, peptidoglycans, zymosan) is expressed by macrophages and myeloid DC, 
whereas  TLR7  (single-stranded  RNA)  is  expressed  by  pDC  and  some  myeloid  cells 
(Diebold et al. 2004). The differential expression of TLRs by different immune cells 
determines  whether  they  respond  to  particular  signals  to  induce  activation  including 
cytokine production. 
 
1.1.6 Adaptors molecules involved in Toll-like receptor signalling. 
   
Upon TLR ligation, signalling cascades are activated through the TIR domain 
containing  adaptors,  such  as  MyD88  and  TRIF  leading  to  cytokine  production.  All 
TLRs,  except  TLR3,  use  MyD88,  whereas  TLR3  only  uses  TRIF.  TLR4  uses  both 
MyD88 and TRIF and TRAM (Akira and Takeda 2004). Activation through MyD88 or   28 
TRIF lead to activation of a cascade of signalling pathways including nuclear factor-ΚB 
(NF-ΚB) and mitogen activated protein (MAP) kinases, which initiate transcription of 
cytokines and other functional molecules (Akira et al. 2003). 
 
1.1.7 Adaptor molecules involved in Toll-like receptor 4 signalling. 
   
TLR4 was first discovered as a receptor for LPS by cloning of the Lps gene in 
the  LPS  non-responsive  C3H/HEJ  mouse  (Poltorak  et  al.  1998)  and  this  was  later 
confirmed in the TLR4 knockout mouse (Hoshino et al. 1999). Recognition of LPS by 
TLR4  requires  several  accessory  molecules,  including  LPS-binding  protein  (LBP), 
CD14, and MD2 (Medzhitov 2001). LPS is first bound to LBP, which transfers LPS 
monomers to CD14 (Wright et al. 1989). CD14 is a high-affinity LPS receptor that can 
be expressed on the surface of APCs or secreted into serum. CD14-deficient mice show 
a defect in responsiveness to LPS (Wright et al. 1990; Haziot et al. 1996). MD2 is a 
small protein that lacks a transmembrane region and is expressed at the cell surface 
together with TLR4 (Shimazu et al. 1999). Its precise function is presently unknown. 
TLR4 is one of the most complex TLR as it utilises a MyD88 dependent and a 
MyD88  independent  signalling  pathway  (Fitzgerald  et  al.  2003).  TLR4  mainly 
recognises  lipopolysaccharide  (LPS)  from  gram-negative  bacteria.  When  TLR4  is 
triggered with LPS, MyD88 and TIRAP (TIR domain-containing adaptor protein) are 
recruited to the Toll/IL-1 receptor (TIR) domain of TLR4. This leads to activation of 
nuclear factor-κB (NF-κB) and MAP kinases through interaction of IRAK and TRAF6, 
which  leads  to  transcription  of  cytokine  genes  (Li  and  Verma  2002).  The  MyD88   29 
independent pathway uses adaptors TRAM (TRIF-related adaptor molecule) and TRIF 
(TIR domain-containg adaptor inducing interferon β) upon ligation of TLR4, which also 
trigger  NF-κB,  MAP  kinase  activation  and  transcription  of  cytokines.  Interferon 
regulatory factor 3 (IRF3) is also activated through TRAM and TRIF, leading to type 1 
interferon (IFN) transcription (Figure 1.1.7) (Akira et al. 2003; Takeda et al. 2003). 
Recent reports showed that protein kinase PKR works downstream of TRIF leading to 
induction of apoptosis in response to certain pathogens that activate TLR4 (Hsu et al. 
2004). PKR also promotes IFN-α production in a TLR-independent manner (Diebold et 
al. 2003). 
 
1.1.8 Adaptor molecules involved in Toll-like receptor 9 signalling. 
 
  TLR9 is an intracellular TLR which is located on endocytic vesicles below the 
plasma membrane (Takeshita et al. 2004). TLR9 was first identified as the receptor for 
CpG using the TLR9 knockout mouse (Hemmi et al. 2000). CpG  is a non-methylated 
DNA motif that is expressed by bacteria, fungi and viruses, but not in mammals (Krieg 
et al. 1995). CpG can be divided into 3 distinct subtypes; CpG-A, B and C, each with its 
own function (Krieg 2002; Guiducci et al. 2006). CpG-A are capable of inducing high 
amounts of IFN-α in pDC (Honda et al. 2005) but are poor at inducing differentiation of 
these cells and induction of costimulators, which lead to B cell activation (Guiducci et 
al. 2006). CpG-B induces expression of costimulators on pDC but lower amounts of 
IFN-α (Guiducci et al. 2006). CpG-C has recently been described as being able to induce   30 
both high levels of IFN-α and costimulators (Guiducci et al. 2006). In our lab we use 
CpG-B. 
When a cell is stimulated with CpG both the TLR9 and the CpG is transported to 
the  endosome,  where  the  signalling  cascade  is  initiated  (Takeshita  et  al.  2004).  The 
signalling cascade uses adaptor protein MyD88 and leads to activation of NF-κB, MAP 
kinases and transcription of inflammatory cytokines (Takeda and Akira 2004). MyD88-
deficient mice have been shown to be unresponsive to CpG, showing that MyD88 is 
essential for CpG mediated signalling (Kawai et al. 1999). To date, no other adaptors for 
TLR9 have been identified (Figure 1.1.8). 
 
1.1.9 Production of proinflammatory and anti-inflammatory cytokines by macrophages 
and DC through TLR stimulation. 
 
  Upon stimulation of macrophages and DC through TLRs, cytokine production is 
induced. This includes the production of proinflammatory cytokines IL-12, TNF and 
interferons. IL-10 can also be induced in both macrophages and myeloid DC but not 
plasmacytoid DC upon TLR stimulation (Boonstra et al. 2006). It has been suggested 
that the IL-10 production observed in the macrophages and myeloid DC is preferentially 
induced  by  stimulation  through  TLR2  and  dectin-1  (Dillon  et  al.  2006).  This  report 
showed that upon stimulation of DC with zymosan, which is recognised by both TLR2 
and C-type lectin, production of IL-10 was enhanced and production of proinflammatory 
cytokines was reduced compared to stimulation with LPS (TLR4). Dillon et al. (2006) 
conclude that the IL-10 production upon TLR2 and Dectin-1 stimulation is regulated by   31 
ERK activation. In another report, it was shown that both macrophages and myeloid DC 
produced  IL-12 and  IL-10 in response to TLR  stimulation through both the MyD88 
dependent  or  the  MyD88  independent  pathway,  whereas  plasmacytoid  DC  did  not 
produce any IL-10 (Boonstra et al. 2006). This indicates that IL-10 can be produced by a 
range of stimuli including TLR ligands and not just through TLR2 and Dectin-1, but its 
production may be restricted to certain cell types.  
 
1.2 Cytokines produced by the innate and adaptive immune response 
 
1.2.1 Interleukin 10 (IL-10). 
 
  IL-10  plays  an  important  role  in  the  control  of  inflammation  by  directly 
inhibiting DC and macrophage function (Bogdan et al. 1991; Fiorentino et al. 1991; 
Fiorentino et al. 1991; Moore et al. 2001). IL-10 is produced by a variety of cell types, 
including activated macrophages, DC, B cells, and mast cells. IL-10 is also secreted by 
T cells, in particular by the effector subset of Th2 cells and under some conditions by 
Th1 and CD8
+ T cells, and by some types of regulatory T cells (O'Garra and Robinson 
2004; O'Garra and Vieira 2004; O'Garra et al. 2004). As discussed earlier, absence of 
IL-10 leads to spontaneous development of inflammatory bowel disease (IBD) (Kuhn et 
al. 1993), showing the importance of IL-10 in regulating immune responses. 
  IL-10  has  been  shown  to  inhibit  production  of  several  proinflammatory 
cytokines, including  IL-1,  IL-6,  IL-12 and TNF.  It also inhibits production of many 
chemokines implicated in the recruitment of monocytes, DC, neutrophils and T cells.   32 
The inhibition of these cytokines and chemokines show how IL-10 plays an important 
role in downregulating inflammatory immune responses (Moore et al. 2001). Studies 
carried out in IL-10 deficient mice show increased production of IL-12 and TNF (Yi et 
al. 2002),  and in infections with lethal doses of Listeria monocytogenes where the IL-10 
receptor was blocked with anti-IL-10R monoclonal antibodies, treated mice survived 
and also had a lower bacterial burden as compared with untreated mice (Silva et al. 
2001).  In  another  infection  with  Toxoplasma  gondii  of  IL-10  deficient  mice,  it  was 
found that these mice compared with littermate controls all died. This was not due to 
uncontrolled infection as parasite numbers were similar in both mice strains, however, 
an increase in IL-12, TNF and IFN-γ was observed. By depleting CD4 T cells, IFN-γ 
levels fell and the mice survived (Gazzinelli et al. 1996). This again confirms the critical 
role of IL-10 in regulating inflammatory responses. For this reason the understanding of 
how IL-10 and proinflammatory cytokines are regulated is of great importance. 
It has been shown that in absence of MAP kinase ERK activation in splenocytes 
and a macrophage cell line, IL-10 production is decreased, whereas, IL-12 production is 
increased possibly by the action of reducing IL-10. This indicates yet another level of 
IL-10 regulation of inflammatory cytokines (discussed in detail later). 
  The molecular mechanisms that regulate expression of the Il-10 gene are poorly 
understood. Recent studies have described changes in the chromatin structure at the Il-10 
locus that relate to the control of Il-10 gene expression in cells that produce this cytokine 
(Ansel et al. 2003; Jones and Flavell 2005; Saraiva et al. 2005; Wang et al. 2005). 
Transcription  factor  NF-κB  have  been  shown  to  regulate  IL-10  induction  in 
macrophages,  as  mice  deficient  in  IKK  developed  severe  atherosclerosis  due  to  low   33 
levels  of  IL-10  when  compared  to  wild  type  mice  (Kanters  et  al.  2003).  A  specific 
chromatin  site  has  been  identified  in  the  IL-10  locus.  This  site  was  only  found  in 
macrophages but not in T cells (Saraiva et al. 2005). This shows that NF-κB plays an 
important part in regulating IL-10 induction and production in antigen presenting cells. 
However,  a  master  regulator  that  initiates  expression  of  the  Il-10  gene,  by  inducing 
remodelling of the Il-10 locus to allow access and function of ubiquitous enhancing or 
silencing  transcription  factors,  has  not  yet  been identified  for  macrophages  and  DC, 
although GATA3 plays an important role in T cells inducing chromatin remodelling of 
the Il-10 locus (Saraiva et al. 2005). At the transcriptional level, Sp1 (Brightbill et al. 
2000), Sp3 (Tone et al. 2000), CCAAT/enhancer-binding protein β (Liu et al. 2003), 
IFN  regulatory  factor-1,  and  STAT3  (Ziegler-Heitbrock  et  al.  2003)  transactivate 
various constructs of the IL-10 promoter in reporter assays, in both mouse and human 
cell lines. Smad-4 (Kitani et al. 2003) and Jun proteins (Wang et al. 2005) have been 
shown to regulate IL-10 expression in primary Th1 and Th2 cells, respectively. Finally 
Ets-1 has been suggested to play a role in repressing the production of IL-10 in Th1 
cells, as Ets-1-deficient mice show an increase in the production of IL-10 (Grenningloh 
et al. 2005). 
 
1.2.2 Interleukin 12 (IL-12). 
 
  IL-12 is an inflammatory cytokine that is produced by DC and macrophages in 
response  to  TLR  triggering.  It  induces  Th1  differentiation  and  IFN-γ  production 
(Trinchieri 2003). IL-12 belongs to a family of structurally similar cytokines, IL-12, IL-  34 
23 and IL-27. IL-12 is a heterodimer composed of a 35kD light chain, p35, and a 40kD 
heavy chain, p40,  forming the bioactive  IL-12p70 (Kobayashi et al. 1989).  IL-23 is 
composed of the p40 chain and a p19 chain. In contrast IL-27 is composed of a p28 
chain and EBI3 or p40 (Figure 1.2.2) (Trinchieri 2003).  
  IL-12p40  can  be  secreted  as  a  homodimer  or  monomer,  since  it  is 
produced in excess over the IL-12p70 and IL-23 heterodimers. IL-12p40 can bind to the 
IL-12 receptor at lower affinity than IL-12p70 or IL-23, but its function is not yet clear 
(Trinchieri 2003). IL-12p70 is produced in high amounts by DC upon TLR ligation. This 
leads to activation of Th1 cells to produce IFN-γ. IL-12 also enhances the phagocytic 
ability of phagocytes and their production of inflammatory cytokines such as IL-6, TNF 
and IL-12 (Ma and Trinchieri 2001). IFN-γ enhances the production of IL-12p70 to form 
a positive feedback loop during inflammatory and Th1 responses (Ma et al. 1996). The 
T  cell  enhancement  of  IL-12p70  production  also  takes  place  through  direct  cell-cell 
interactions, primarily through ligands of the TNF family such as CD40L (Schulz et al. 
2000). 
IL-12p40 can be secreted as a homodimer or monomer, since it is produced in 
excess  over  the  IL-12p70  and  IL-23  heterodimers.  IL-12p40  can  bind  to  the  IL-12 
receptor  at  lower  affinity  than  IL-12p70  or  IL-23,  but  its  function  is  not  yet  clear 
(Trinchieri 2003). IL-12p70 is produced in high amounts by DC upon TLR ligation. This 
leads to activation of Th1 cells to produce IFN-γ. IL-12 also enhances the phagocytic 
ability of phagocytes and their production of inflammatory cytokines such as IL-6, TNF 
and IL-12 (Ma and Trinchieri 2001). IFN-γ enhances the production of IL-12p70 to form 
a positive feedback loop during inflammatory and Th1 responses (Ma et al. 1996). The   35 
T  cell  enhancement  of  IL-12p70  production  also  takes  place  through  direct  cell-cell 
interactions, primarily through ligands of the TNF family such as CD40L (Schulz et al. 
2000). 
IL-12p70  is  a  very  potent  cytokine  to  induce  Th1  differentiation  which  is 
important for the eradication of pathogens. However, the tight regulation of IL-12p70 is 
critical as too much IL-12 can lead to uncontrolled Th1 differentiation, which can cause 
pathology  (O'Garra  1998).  Studies  in  IL-10  deficient  splenocytes  show  that  IL-12 
production  is  elevated  (Yi  et  al.  2002),  indicating  the  importance  of  IL-10  in 
downregulating  IL-12  production.  Consistently,  IL-10  has  been  found  to  block  the 
transcription of both the p40 and p35 genes (Zhou et al. 2004).  
The role of IL-23 is important in the establishment and maintenance of organ-
specific inflammatory autoimmune diseases (Cua et al. 2003; Murphy et al. 2003). IL-23 
deficient mice show normal immune responses to intracellular pathogens, whereas IL-
12p35 deficient mice cannot mount a Th1 immune response but are highly susceptible to 
autoimmunity (Langrish et al. 2005). One report showed that collagen-induced arthritis 
is  blocked  in  IL-23  knockout  mice,  whereas  IL-12  deficient  mice  showed  enhanced 
pathology (Murphy et al. 2003). Another report shows that the role of IL-12 and IL-23 
are different in induced inflammatory bowel disease (IBD). In CD40-induced colitis IL-
23 was responsible for induction of inflammation but not wasting disease or enhanced 
proinflammatory  serum  cytokine  production,  whereas  IL-12  was  responsible  for 
systemic inflammation (Uhlig et al. 2006). Taken together this indicates that IL-23 has 
an important role in autoimmune responses.  
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1.2.3 Tumour necrosis factor (TNF). 
 
  TNF is an inflammatory cytokine, which was first identified about 30 years ago, 
as  a  cytokine  produced  by  the  activated  immune  system,  which  was  able  to  exert 
cytotoxicity on tumour cell lines and cause tumour necrosis in animal models (Wajant et 
al. 2003). TNF is primarily produced as a type II transmembrane protein arranged in 
stable  homotrimers  and  the  soluble  form  is  released  by  proteolytic  cleavage  by  the 
metalloprotease  TNF  alpha  converting  enzyme  (TACE)  (Black  et  al.  1997).  TACE 
belongs to a family of mammalian metalloproteases called adamlysins (ADAMs) (Soond 
et al. 2005). TACE cleaves the membrane bound TNF in order to release the active 
soluble form (Wajant et al. 2003). It has been shown that ERK can phosphorylate TACE 
at threonine 735 in LPS stimulated macrophages leading to activation and cleavage of 
TNF, showing that TACE is a physiological substrate for ERK1/2 in LPS stimulated 
macrophages (Soond et al. 2005; Rousseau et al. 2008). Rousseau et al (2008), further 
suggested that phosphorylation of TACE at threonine 735 may be a prerequisite for the 
LPS stimulated cell surface expression and cleavage of pre-TNF. However, they also 
showed that inhibition of ERK did not affect the transport of pre-TNFα from the Golgi 
to  the  plasma  membrane  and  thus  did  not  affect  levels  of  membrane  bound  TNF. 
However, levels of soluble TNF were reduced upon inhibition of ERK showing that Tpl-
2/ERK1/2 is crucial for processing of pre-TNFα to the secreted form of TNF. 
  Once TNF has been cleaved it exerts its effects by binding to either a 55kDa 
TNF receptor (TNFR1) or a 75kDa TNF receptor (TNFR2). The TNFR family proteins 
are type I transmembrane proteins containing conserved cysteine-rich domains. Binding   37 
of  TNF  to  its  receptor  results  in  receptor  trimerisation  and  initiation  of  signal 
transduction  (Arron  et  al.  2002;  Wajant  et  al.  2003).  Signal  transduction  can  occur 
through protein binding to the TNFR intracellular extension, which contains a death 
domain, but also through a family of adapter proteins called TNFR-associated factor 
(TRAF) (Vandenabeele et al. 1995; Arron et al. 2002). The death domain-containing 
proteins shown to bind to the TNFR include TNFR-associated death domain (TRADD), 
which  can  bind  the  additional  signal  transducer  TRAF  (Yuasa  et  al.  1998).  TRAF 
proteins consist of a family of six proteins, which can interact directly or indirectly with 
members of the TNFR superfamily. TRAF proteins mediate the assembly of cytoplasmic 
signalling complexes at the TNFR. TRAF can activate the signalling pathway leading to 
the activation of NF-κB and AP-1 (Arron et al. 2002; Beinke and Ley 2004). TRAF 
proteins can also activate members of the mitogen-activated protein kinase (MAPK) 
family (Raingeaud et al. 1995).  
TNF uses TNFR1 and TNFR2 for signal transduction. TNFR1 contains a death-
domain and does not bind directly to TRAF proteins, whereas TNFR2 does not have a 
death-domain, but can interact directly with TRAF proteins (Arron et al. 2002). TNFR1 
recruits TRADD to its receptor complex. This can either lead to recruitment of FADD, 
which activates the caspase cascade leading to apoptosis, or TRAF2 can be recruited 
initiating  the  activation  of  NF-κB  and  AP-1.  TNFR2  can  bind  directly  to  TRAF2 
activating survival pathways (Arron et al. 2002). 
  AU-rich  elements  (ARE)  found  in  the  3’-untranslated  region  of  transcripts 
encoding  cytokines,  growth  factors,  oncogenes  and  transcription  factors  have  been 
shown to regulate mRNA stability and translation (Kontoyiannis et al. 1999). Bioactive   38 
TNF has many actions and therefore the biosynthesis is under the control of several 
factors. It has been indicated that there are additional translational controls in the 3’-
untranslated region of Tnf mRNA, as experiments using reporter constructs transfected 
into cell lines show no activity in cells that lack of the 3’-untranslated region of Tnf 
mRNA (Han et al. 1990). In another study, it was found that LPS induced JNK plays a 
role in the translational activation of tnf mRNA as a kinase dead mutant of JNK blocked 
the activation of the translational blockade imposed by the 3’-untranslated region of Tnf 
mRNA (Swantek et al. 1997). TNF transcription has also been found to be controlled by 
several  transcription  factors  including  NF-  κB  (de  Winther  et  al.  2005)  and  NF-AT 
(Collart et al. 1990; Tsytsykova et al. 2007). 
In  a  study  on  TNF  ARE  it  was  found  that  mice  were  lacking  TNF  ARE 
(TNF
∆ARE) had elevated levels of TNF in their sera as compared to the wildtype control 
(Kontoyiannis et al. 1999). Upon LPS administration the level of TNF rose 3-fold as 
compared  to  controls.  Macrophages  from  TNF
∆ARE  mice  also  showed  elevated 
production of TNF in the absence of stimulation. These results were also confirmed at 
the mRNA level. This group also found that the TNF
∆ARE mice showed reduced weight 
gain and increased mortality within 5-12 weeks of age as a consequence of increased 
TNF in the serum. Kontoyannis et al. (1999) conclude that in the absence of stimulation 
ARE acts as determinants of Tnf mRNA instability, but upon LPS stimulation the ARE 
mediate posttranscriptional enhancement of Tnf mRNA accumulation. 
Another  study  showed  that  mice  deficient  in  Tpl-2/ERK  showed  normal  Tnf 
mRNA induction but TNF protein was dramatically reduced in response to stimulation 
with LPS, suggesting that ERK regulates TNF at the post-transcriptional level. These   39 
Tpl-2 deficient mice were found to be resistant to LPS induced septic shock, due to 
defective TNF protein production (Dumitru et al. 2000).  
However, in the study by Rousseau et al. (2008), it was shown that Tnf mRNA 
induction was reduced although not completely inhibited in macrophages from Tpl-2 
deficient  mice  upon  LPS  stimulation.  This  reduction  in  Tnf  mRNA  expression  was 
shown to be time dependent as by 6 hours of stimulation the Tnf mRNA levels in the 
Tpl-2 deficient mouse were the same as compared to the wildtype control. All these 
studies indicate that TNF regulation is complex as the Tpl-2/ERK pathway is important 
in controlling the maturation of pre-TNF to TNF, but also plays a role in the production 
of pre-TNF at the level of transcription/translation. 
TNF is produced by many immune cells but high levels are induced in DC and 
macrophages in response to pathogens.  In macrophages the action of TNF has been 
shown  to  upregulated  pathways  such  as  iNos  and  ROI  to  affect  the  killing  of 
intracellular pathogen (Taylor et al. 2005). On the other hand, high concentrations of 
TNF are critical in the development of septic shock, whereas, prolonged exposure to low 
concentrations  of  TNF  can  cause  wasting  disease  and  many  inflammatory  disorders 
(Vassalli  1992;  Feldmann  et  al.  2005)  and  therefore  it  is  important  that  the  TNF 
response is regulated (Wajant et al. 2003). Consistent with its strong proinflammatory 
and immunostimulatory properties, TNF has been shown to be an important mediator of 
autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, which can be 
effectively treated with anti-TNF antibodies (Choy and Panayi 2001; Feldmann et al. 
2005). In keeping with its role in the host defense TNF has been shown to play an 
important  role  in  the  defence  against  many  intracellular  pathogens  such  as   40 
Mycobacterium tuberculosis, Listeria monocytogenes, and Leishmania major in mouse 
models of disease (Flynn et al. 1995; Vieira et al. 1996; Mocci et al. 1997). Indeed 
treatment of rheumatoid arthritis or Crohn’s disease with anti-TNF antibodies has been 
shown to lead to reactivation of latent TB (Keane 2005). 
 
1.2.4 Interferons. 
 
  IFN is divided into many distinct types. Type I IFN include IFN-α and IFN-β and 
are produced in response to viral and intracellular infections by DC and macrophages. 
Type II IFN is composed of IFN-γ, which is structurally unrelated to Type I IFN. IFN-γ 
is produced mainly by Th1 cells, NK cells and CD8
+ T cells. Type III IFN genes are a 
relatively newly described family and are induced in virally infected cells (Honda et al. 
2006).  
  Type I IFN was described nearly 50 years ago, as a soluble factor produced by 
virally infected cells (reviewed in (Stetson and Medzhitov 2006). It has later been shown 
that  pDC  are  mainly  responsible  for  the  production  of  high  levels  of  type  I  IFN, 
particularly  IFN-α,  during  the  early  stages  of  a  viral  infection  (Asselin-Paturel  and 
Trinchieri 2005). The early production of type I IFN can inhibit production of IL-12 
(Dalod  et  al.  2002).  However,  the  effects  of  type  I  IFN  on  IL-12  production  are 
complex, as high levels of IFN blocks IL-12 production by decreasing the transcription 
of the IL-12p40 chain, whereas  low levels of IFN are required for transcription of the 
IL-12p35 chain (Gautier et al. 2005).    41 
  Type I IFN production is primarily controlled at the transcriptional level where a 
family of transcription factors, Interferon Regulatory Factors (IRF), play an important 
role. IRF can be divided into several family members named IRF1 to IRF9 (Mamane et 
al. 1999). IRF3 and IRF7 are highly homologous and are the key players in IFN type I 
gene expression. IRF7 forms homodimers or heterodimers with IRF3 and each of these 
dimers act differentially on type  I  IFN family  members.  IRF3  activates  IFN-β more 
potently than IFN-α, whereas IRF7 activates both IFN-α and IFN-β (Honda et al. 2006).  
  Two  pathways  for  type  IFN  I  induction  have  been  identified,  triggered 
respectively by cytosolic pattern recognition receptors (RIG-I and MDA5) and TLRs 
(Stetson  and  Medzhitov  2006).  All  TLRs  except  TLR3  activate  MyD88  which  can 
induce type I IFN production in response to TLR ligands, for example, pDC induce high 
levels of type I IFN through TLR7 and TLR9. MyD88 interacts directly with IRF7 but 
not IRF3 (Honda et al. 2004; Kawai et al. 2004). TLR3 and TLR4 use the adaptor TRIF, 
which interacts directly with IRF3. TLR4 is the only receptor to use both MyD88 and 
TRIF upon LPS ligation leading to IFN-β production but not IFN-α in macrophages and 
myeloid DC (Honda et al. 2006).  
Recently, it was shown that MyD88 recruits TRAF3 and TRAF6 to induce type I 
IFN (Hacker et al. 2006). It was shown that TRAF3 was essential for type I IFN and IL-
10  induction,  whereas  TRAF6  was  essential  for  other  proinflammatory  cytokine 
production.  It  was  shown  that  TRAF3  deficient  myeloid  cells  stimulated  with  LPS 
(TLR4) or CpG (TLR9) synthesised high levels of IL-12, but no IL-10 or type I IFN. 
Poly(I:C)  (TLR3)  also  did  not  induce  type  I  IFN  in  TRAF3  deficient  cells.  TRAF6   42 
deficient cells stimulated with CpG lead to reduced IL-12 and IL-10 but no type I IFN 
production (Hacker et al. 2006).   
 
1.3 Signalling pathways in dendritic cells and macrophages 
 
1.3.1 Nuclear factor-κB transcription factors. 
 
  Upon TLR stimulation, several signalling pathways are activated. These include 
the NF-κB and MAP kinase pathways. Nuclear factor-κB (NF-κB) transcription factors 
play a critical role in regulating innate and adaptive immune responses (Li and Verma 
2002). NF-κB dimers are held in the cytoplasm by NF-κB inhibitory (IκB) proteins. 
Upon agonist stimulation, IκBs are degraded, leading to NF-κB dimer release, entry to 
the  nucleus  and  their  binding  to  NF-κB  sites  in  promoters  of  target  genes  and 
modulation of gene expression.  
The NF-κB transcription factor family compromises five members, RelA (p65), 
RelB, c-REL, NF-κB1 (p50) and NF-κB2 (p52) (Li and Verma 2002). Each of these has 
a  conserved  Rel-homology  domain  at  the  N-terminus,  which  contains  the  nuclear 
localisation signal and DNA binding domains. NFκB1 and NFκB2 are synthesized as 
large precursors of 105kDa (p105) and 100kDa (p100), respectively. These are partially 
proteolysed  by  the  proteasome  (termed  processing),  which  removes  their  C-terminal 
halves, to produce the active NF-κB1 p50 and NF-κB2 p52 subunits (Beinke and Ley 
2004). The IκB family includes IκBα, IκBβ, and IκBε (Li and Verma 2002). NF-κB1 
precursor, p105, and NF-κB2 precursor, p100, also function as IκBs containing IκB-like   43 
C-terminal  halves,  which  retain  REL  proteins  in  the  cytoplasm  (Belich  et  al.  1999; 
Pomerantz and Baltimore 2002). 
  TLR stimulation activates the  IKK complex (IKK1,  IKK2 and  NEMO). This 
leads to phosphorylation, ubiquitination and proteasome-mediated proteolysis of the IκB 
family by members of the IκB kinase (IKK) family. NF-κB subunits are released and 
enter the nucleus to transcribe cytokine genes. 
There are three signalling pathways, by which NF-κB is activated. These are the 
canonical, p105 and the alternative p100 pathways. In the canonical pathway, the NF-κB 
dimer p65/p50 is held in the cytoplasm by IκBα (Pomerantz and Baltimore 2002). In the 
p105 pathway, p50 dimers are held by p105. In the alternative pathway, p100 retains 
RelB in the cytoplasm. (Beinke and Ley 2004). Upon stimulation of these pathways, 
IKK1 or IKK2 phosphorylate the relevant IκB, p105 or p100, leading to proteolysis by 
the proteasome and release of active dimers. These pathways are activated in response to 
different stimuli.  
 
1.3.2 MAP Kinases. 
 
MAP kinases are evolutionarily conserved in eukaryotes and play an important 
role in cell differentiation, cell movement, cell division, and cell death (Schaeffer and 
Weber 1999). MAP kinases can be divided into three main groups: the extracellular 
signal-regulated protein kinases 1/2 (ERK), the p38α/β/γ/δ MAP kinase, and the c-Jun 
NH2-terminal kinases 1/2/3 (JNK) (Chang and Karin 2001; Symons et al. 2006). MAP 
kinases are activated by phosphorylation on conserved tyrosine and threonine residues in   44 
the activation loop by dual-specificity MAP kinase kinases (MAP2-Ks), which are in 
turn, phosphorylated on conserved serine and threonine residues by MAP kinase kinase 
kinases (MAP3-Ks) (Marshall 1994). ERK1/2 MAP kinases are activated by MEK1/2 
(MAP2-K). JNK1/2/3 are activated by MKK4 and MKK7. p38 is activated by MKK3 
and  MKK6.  These  MAP-2K  are  themselves  activated  by  several  different  MAP3-K 
(Dong et al. 2002; Symons et al. 2006). 
 
1.4 Extracellular signal-regulated protein kinase (ERK) 
 
1.4.1 ERK activation control by Raf. 
 
Raf  is  a  serine/threonine  kinase,  which  is  activated  by  a  series  of  events 
including recruitment to the plasma membrane mediated by Ras-GTP, dimerisation of 
Raf  proteins,  phosphorylation  and  association  with  scaffold  complexes such  as  KSR 
downstream of antigen and mitogen receptors in lymphocytes (McCubrey et al. 2007). 
Ras is a small GTP-binding protein, which is the common upstream molecule of several 
signalling pathways including Raf; MEK; ERK pathway, PI3K and AKT (Yoon and 
Seger 2006; McCubrey et al. 2007) 
Raf specifically activates MEK but not other MAP2-K. The interaction of MEK 
with Raf is dependent on a proline-rich sequence only found in MEK and not other 
MAP2-K. Deletion of this proline-rich sequence has been shown to diminish the ability 
of Raf to activate MEK (Schaeffer and Weber 1999). Raf can be subdivided into three 
groups,  A-Raf,  which  preferentially  activates  MEK1,  c-Raf-1,  which  activates  both   45 
MEK1 and MEK2 equally well and B-Raf, which binds to both MEK1 and MEK2 but 
activates MEK1 better than MEK2 (Schaeffer and Weber 1999). 
The Ras/Raf/MEK/ERK pathway (Figure 1.4.1) can be activated by a wide range 
of stimuli including epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-
1),  platelet-derived  growth  factor  (PDGF),  nerve  growth  factor  (NGF)  and  phorbol 
esters. This wide range of stimuli all activate the same MAP kinase pathway but with 
different end results (Marshall 1995). This leads to the question of how a specific signal 
induces  a  specific  response  when  activating  a  signaling  pathway  shared  by  many 
receptors.  
 
1.4.2 Scaffold proteins. 
 
Scaffold proteins have been shown to interact with components of MAP kinase 
pathways and found to play an important part in regulating MAP kinase signalling by 
creating a functional signaling molecule and to maintain the specificity of the signal 
transduction  (Morrison  and  Davis  2003;  Sacks  2006).  Several  functions  have  been 
proposed for scaffold proteins. 1). Binding to the scaffold may be necessary for kinase 
activation,  2).  Scaffold  proteins  may  allow  for  faster  signalling  by  inhibition  of 
phosphatases, 3). Scaffold proteins may recruit other kinases to the receptor, 4). Scaffold 
proteins can control protein interaction and 5). Scaffold proteins can control subcellular 
location (Sacks 2006).  
Several scaffold proteins have been shown to play a role in the ERK signalling 
pathway. These include; KSR (Kinase suppressor of Ras), MP1 (MEK-partner 1), β-  46 
Arrestin-1 and –2, MEKK1 (MEK kinase 1), CNK  (connector enhancer of KSR), SUR-
8 (suppressor of Ras-8) and IQGAP1 (Morrison and Davis 2003; Sacks 2006). Evidence 
suggests that KSR binds directly to c-Raf-1, MEK1/2 and ERK1/2. KSR and MEK are 
constitutively associated, whereas binding to c-Raf-1 and ERK occurs through activation 
of Ras. In studies using cells from KSR deficient mice, it was found that KSR modulates 
the intensity and duration of the ERK signal. KSR was found to be required for maximal 
ERK activation (Kortum et al. 2005; Kortum et al. 2006). 
MP1 associates with MEK1 and ERK1, where it promotes signalling between 
MEK  and  ERK.  β-Arrestins  interacts  with  Raf,  MEK  and  ERK  contributing  to  G-
protein-coupled  receptor  (GPCR)  mediated  activation  of  ERK.  MEKK1  acts 
constitutively with c-Raf-1, MEK1 and ERK2. CNK and SUR-8 interact with Raf kinase 
and play a role in coupling membrane signalling events to Raf activation. IQGAP1is a 
widely  expressed  protein  that  binds  directly  to  MEK1/2  and  ERK1/2  after  EGF 
activation (Morrison and Davis 2003; Sacks 2006).  
 
1.4.3 Control of ERK activation by Tumour progression locus-2 (Tpl-2); (MAP3K8). 
 
  Tpl-2 or Cot was originally described as a proto-oncogene in T cell lymphomas 
(Patriotis et al. 1993; Erny et al. 1996; Ceci et al. 1997). Tpl-2 is a proto-oncogene 
encoding a serine-threonine kinase and was identified as the target for provirus insertion 
in MMLV in the last intron leading to the enhanced expression of a carboxy-terminally 
truncated protein. This leads to activation of Tpl-2 (Ceci et al. 1997).    47 
  Studies  in  cell  lines  have  shown  that  overexpressed  Tpl-2  activates  the  ERK 
MAPK pathway (Patriotis et al. 1994; Salmeron et al. 1996; Chiariello et al. 2000). In 
vitro experiments have shown that this activity results from Tpl-2 acting as a MAP-3 
kinase for MEK1 and -2 (MAP-2 kinase), which phosphorylates ERK (Salmeron et al. 
1996; Chiariello et al. 2000) (Figure 1.4.3). It is now known that Tpl-2 functions as a 
MAP3K in innate immune cells (Symons et al. 2006). A Tpl-2 knockout mouse was 
generated in order to study the physiological effects of Tpl-2 (Dumitru et al. 2000). Tpl-
2 deficient macrophages stimulated with LPS were unable to phosphorylate MEK and 
ERK, but the activation of p38 and JNK MAP kinases were normal. It was shown that 
the Tpl-2 knockout mouse was resistant to LPS induced endotoxic shock, due to a defect 
in the TNF mRNA transport (Dumitru et al. 2000).  
  Tpl-2  binds  to  the  C-terminal  half  of  NF-κB1  (p105)  (Belich  et  al.  1999).  I 
unstimulated macrophages Tpl-2 does not exist in a p105-free form, and p105 deficient 
macrophages suggests that p105 is needed for Tpl-2 stability (Beinke et al. 2003). Tpl-2 
is held in its inactive state by binding to p105 and upon stimulation of macrophages, 
Tpl-2  is  released  from  p105  in  order  to  exert  its  MAPK  properties  on  ERK.  The 
truncated oncogenic form of Tpl-2 is unable to form a stable complex with p105 and is 
therefore able to cause persistent phosphorylation of MEK (Cowley et al. 1994; Beinke 
et al. 2003). 
  It  has  been  shown  that  that  Tpl-2  is  essential  for  induction  of  ERK  in 
macrophages (Dumitru et al. 2000; Eliopoulos et al. 2003) and in DC (Sugimoto et al. 
2004). In unstimulated cells Tpl-2 forms a ternary complex with NF-κB1 p105 and A20-
binding inhibitor of NF-κB 2 (ABIN-2), which are both required for Tpl-2 stability.   48 
Upon TLR stimulation Tpl-2 is released from the complex, which is required for its 
activation (Beinke et al. 2003; Lang et al. 2004). It has been shown that Tpl-2 release 
from NF-κB1 is not sufficient for ERK phosphorylation but phosphorylation of the C-
terminal of Tpl-2 is also required before it can induce ERK activation (Robinson et al. 
2007).  ABIN-2  has  been  shown  to  be  essential  for  Tpl-2  protein  stability  and 
consequently ABIN-2 deficient macrophages stimulated with LPS show reduced ERK 
activation, due to downregulation of Tpl-2. However, ABIN-2 is not required for Tpl-2 
activation (Papoutsopoulou et al. 2006). 
    
1.4.4 Importance of ERK regulation. 
 
Regulation of ERK is essential as uncontrolled activation of ERK through either 
the Ras/Raf or Tpl-2 pathway has been implicated in many cancers (Patriotis et al. 1993; 
Patriotis et al. 1994; Ceci et al. 1997; McCubrey et al. 2007; Tsatsanis et al. 2008). 
Stimulation  of  the  ERK  pathway  leads  to  activation  of  various  transcription  factors 
including c-Fos, Ets, Elk1, c-Myc, c-Jun and CREB, as well as regulation of apoptosis 
by phosphorylation of Bad, Bcl-2 and caspase-9 (Marshall 1994; McCubrey et al. 2007). 
The outcome of signalling through the ERK MAP kinase pathway depends on whether 
the signal is transient or sustained. In studies using PC12 neuronal cells, it has been 
found  that  stimulation  with  NGF  causes  differentiation  of  the  PC12  cells  due  to 
sustained ERK activation, whereas stimulation with EGF leads to proliferation of the 
cells due to transient ERK activation (Marshall 1995; Keyse 2000; Murphy and Blenis 
2006). The correlation between transient and sustained ERK activation with respect to   49 
alteration of cell behaviour has also been found in fibroblasts, macrophages and T cells 
(Murphy and Blenis 2006). Sustained ERK activation can be achieved by mutations in 
components of the Ras/Raf/MEK/ERK pathway leading to carcinogenesis.  
One of the targets of the ERK cascade is the Elk1 transcription factor, which 
belongs to the family of Ets-domain transcription factors. Elk1 directly interacts with 
ERK at two docking sites present in both ERK and Elk1,  directly phosphorylated by 
Elk1 (Yoon and Seger 2006). Another transcription factor activated by ERK is c-Fos. 
This is one of the earliest transcriptional events to take place after cell stimulation. c-Fos 
and  c-Jun  comprises  one  form  of  AP-1,  which  is  an  important  regulator  of    early 
transcriptional  processes.  The  regulation  of  c-Fos  is  very  important  as  it  controls 
proliferation, differentiation and oncogenic transformation. (Eferl and Wagner 2003). 
The phosphorylation of c-Fos requires active ERK and RSK  in the nucleus, which is 
achieved after sustained stimulation of the ERK pathway (Yoon and Seger 2006). 
Other  substrates  of  ERK  includes  the  MAP  kinase  activated  protein  kinases 
(MAPKAPs).  These  include  RSK1-4,  MNK1/2,  MSK1/2,  MAPKAPK3  and 
MAPKAPK5. The RSK family is a key component of the ERK signalling cascade, as it 
contributes to both cytosolic and nuclear signalling and can dictate a number of ERK-
mediated cellular outcomes such as prevention of apoptosis and induction of the cell 
cycle  (Yoon  and  Seger  2006).  The  other  MAPKAPs  activated  by  ERK  are  not 
specifically ERK substrates as they can also be phosphorylated by p38, but are also 
required  for  ERK  signalling  with  additional  substrates  necessary  for  ERK-mediated 
responses (Roux and Blenis 2004). 
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1.4.5 Phosphatases. 
 
Regulation of ERK MAP kinase activity is essential as this kinase controls a 
range of cellular functions such as proliferation, differentiation and apoptosis. In order 
for a MAP kinase to become activated, phosphorylation is required on the tyrosine and 
threonine  residues  within  the  activation  loop  but  dephosphorylation  of  either  of  the 
residues is sufficient for inactivation (Keyse 2000; Martin et al. 2005). Phosphatases are 
responsible for this dephosphorylation. They can be divided into three groups; the dual 
specificity  phosphatases,  which  dephosphorylate  both  the  tyrosine  and  threonine 
residues on ERK2 MAP kinase, the tyrosine-specific phosphatases  (PTPases), which 
dephosphorylate the tyrosine residue on ERK2 MAP kinase and the serine/threonine-
specific phosphatases, which dephosphorylate either the serine or the threonine residue 
on ERK2 MAP kinase (Keyse 2000; Saxena and Mustelin 2000; Martin et al. 2005; 
Owens and Keyse 2007). MAP kinase phosphatases (MKP) act to dephosphorylate and 
inactivated  MAP  kinase  isoforms.  Some  MKPs  are  encoded  by  genes  which  are 
transcriptionally upregulated upon MAP kinase activation. Individual MKPs can also 
differentially regulate MAP kinase isoforms. Overall, MKPs form a negative regulatory 
network that controls MAP kinase activity (Owens and Keyse 2007). 
The dual-specificity phosphatases consists of a family of 10 MKPs, which are 
structurally  similar.  They  can  be  subdivided  into  three  groups  dependant  on  their 
actions. The first group comprises the inducible nuclear phosphatases DUSP1, DUSP2, 
DUSP4 and DUSP5. The second group contains the cytoplasmic related phosphatases 
DUSP6, DUSP7 and DUSP9, which preferentially inactivates ERK. The third group   51 
consists of DUSP8, DUSP10 and DUSP16, which show substrate selectivity towards 
JNK and p38 (Owens and Keyse 2007). In two studies using a DUSP1 deficient mouse, 
it  was  found  that  these  mice  were  highly  susceptible  to  endotoxic  shock  upon  LPS 
injection as compared to wildtype controls. Elevated levels of TNF, IL-6 and IL-10 were 
found in the serum from these mice (Chi et al. 2006; Hammer et al. 2006). Bone marrow 
derived  macrophages  from  DUSP1  deficient  mice  also  produced  increased  levels  of 
TNF, IL-6 and TNF upon stimulation with LPS, whereas IL-12p40 levels were normal 
as compared to wildtype macrophages (Hammer et al. 2006).  
The  protein  tyrosine  phosphatases  were  first  identified  in  yeast  and  some 
mammalian homologues have since then been identified such as STEP (Striatal enriched 
phosphatase),  PTP-SL  (STEP-like  phosphatase),  HePTP  (Haemopoietic  phosphatase) 
and LC-PTP (Leukocyte phosphatase). STEP and PTP-SL are found in neuronal cells 
where  they  were  found  to  physically  associate  with  ERK.  The  lymphoid  specific 
phosphatases  HePTP  and  LC-PTP  were  found  to  block  antigen-dependent  T  cell 
activation  and  cellular  targets  of  these  phophatases  were  identified  as  ERK  (Keyse 
2000). 
Activated  MAP  kinases  are  also  substrates  for  the  cytosolic  serine/threonine 
phosphatases, PP2A and PP2C (Saxena and Mustelin 2000; Martin et al. 2005). PP2A 
has been indicated to play a major role in downregulating the ERK pathway, where it 
can act on both MEK and ERK (Saxena and Mustelin 2000). 
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1.4.6 The role of Tpl-2/ERK induction of IL-10 and IL-12. 
 
Studies using the Tpl-2 knockout mouse, show that not only TNF production is 
reduced upon TLR stimulation of macrophages (Dumitru et al. 2000), but also IL-12p40 
production  is  increased  due  to  abrogation  of  ERK  phosphorylation  (Sugimoto  et  al. 
2004). ERK1 knockout mice have been shown to have reduced IL-10 and increased IL-
12p70 production upon TLR stimulation of DC (Agrawal et al. 2006). Based on these 
studies, ERK has been proposed to function as a negative regulator of Th1 immune 
responses.  Consistent  with  this  hypothesis  infection  of  Tpl-2  deficient  mice  with 
Leishmania major led to a skewed Th1 response (Sugimoto et al. 2004), and conversely 
ERK1  knockout  mice  were  shown  to  have  increased  susceptibility  to  experimental 
autoimmune encephalomyelitis (Agrawal et al. 2006). 
Furthermore, ERK phosphorylation has been implicated in the regulation of IL-
10 and IL-12 in macrophages although the mechanism is not clear as of yet (Yi et al. 
2002; Agrawal et al. 2003). The role of ERK activation in regulation of these cytokines 
in DC is controversial, as there have been conflicting reports claiming that ERK does 
play a role (Agrawal et al. 2003) or ERK does not play a role (Hacker et al. 1999). 
  MAP kinases play an important part in regulating the immune system. Activation 
of the MAP kinases signalling cascade as discussed earlier is required for transcriptional 
regulation  of  the  inflammatory  cytokine  TNF.  A  possible  role  of  ERK  activation  in 
macrophages  for  induction  of  IL-10  has  also  been  found,  where  absence  of  ERK 
activation lead to increased IL-12 (Yi et al. 2002), although it is unclear whether the 
effects on IL-12 are direct or via action on IL-10.   53 
In DC, there are two conflicting studies with respect to ERK activation. One 
finds that ERK phosphorylation cannot be induced in DC upon TLR stimulation but only 
in  macrophages  (Hacker  et  al.  1999).  The  other  shows  that  ERK  activation  in  DC 
induces IL-10 and low levels of IL-12 and upon ERK inhibition, the IL-12 levels are 
increased, while IL-10 was decreased (Agrawal et al. 2003). However, it is not known 
whether  the  upregulation  of  IL-12  seen  in  the  absence  of  ERK  activation  is  the 
consequence of decreased IL-10 or via direct ERK activation alone.  Little is known 
about the role of MAP kinase activation on the production of type I IFN, although one 
study  suggests  that  IL-10  and  type  I  IFN  are  co-ordinately  regulated  (Hacker  et  al. 
2006). For more detail on IL-12 and IL-10, please see section 1.2. 
 
1.5 Aims of the project 
 
We wanted to investigate the role ERK has in regulating cytokine production in 
DC and macrophages stimulated with TLR ligands LPS and CpG focussing particularly 
on production of TNF,  IL-10,  IL-12p40,  IL-12p70 and  IFN-β, as no systematic and 
thorough studies have been carried out on these cytokines, which plays a key role in 
innate and/or adaptive immune responses as discussed earlier. We used two different 
approaches to study this. One was inhibition of ERK activation with a pharmacological 
MEK inhibitor that blocks ERK activation downstream of MEK. The second approach 
was  using  genetically  modified  mice  lacking  Tpl-2.  With  these  approaches  we  have 
found that in DC and macrophages IL-12 was regulated negatively through IL-10, but   54 
also through direct ERK activation in the complete absence of IL-10. We also show that 
Tpl-2 not only regulates ERK activation but also affects activation of p38. 
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Figure 1.2.2: IL-12 family members from (Trinchieri 2003) 
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Chapter 2 
Material and methods   62 
2.1 Plastics 
 
2.1.1 Tissue culture. 
For all types of tissue culture 6-well, 12-well, and 24-well plates (Corning Incorporated, 
USA), 60mm tissue culture dishes (Nunc, Denmark), 60mm petridishes (Sterillin, UK), 
50ml and 15ml Falcon tubes (Corning Incorporated, USA), 70µm cell strainers (BD, 
USA) were used. 
 
2.1.2 ELISA. 
For ELISA 96-well Maxisorp immuno plates (Nunc, Denmark) were used. 
 
2.1.3 Miscellaneous. 
1.5ml  tubes  (Corning  Incorporated,  USA)  were  used  for  RNA,  DNA  and  protein 
samples. 0.2ml Thermostrip PCR tubes (ABgene, UK) were used for PCR reactions. 96-
well PCR plates (ABgene, UK) were used for real time PCR reactions. 1ml syringes 
(BD, USA) and 25G needles (BD, USA) were used for homogenising cells for RNA 
purification.  
 
2.2 Chemicals and buffers 
 
2.2.1 Radio-Immunoprecipitation Assay Lysis buffer (RIPA). 
For lysis of cells for Western blot, RIPA lysis buffer consisting of 1% (v/v) NP40 (BHD 
Laboratory  Suppliers,  UK),  0.1%  (v/v)  SDS  (Biorad,  Germany),  0.5%  (w/v),   63 
deoxycholate acid (Sigma, USA), 50mM Tris HCl pH 8 (Sigma, USA), 150mM NaCl 
(Sigma,  USA),  2mM  EDTA  (Sigma,  USA),  2mM  Sodium-Pyrophosphate  (Sigma, 
USA), 50mM sodium fluoride (Sigma, USA), 100mM vanidate (Sigma, USA) and 10µl 
complete  EDTA-free  protease  inhibitor  cocktail  (Roche  Diagnostics,  Germany)  was 
used. 
 
2.2.2 4x Resolving gel buffer. 
The resolving gel buffer was made from 1.5M TRIS (Sigma, USA), 0.4% (v/v) SDS 
(Biorad, Germany), in distilled H20 and the pH was adjusted to 8.8 with HCl. 
 
2.2.3 4x Stacking gel buffer. 
The stacking gel buffer was made from 0.5M TRIS (Sigma, USA), 0.4% (v/v) SDS 
(Biorad, Germany), in distilled H20 and the pH was adjusted to 6.8 with HCl. 
 
2.2.4 SDS-acrylamide SDS-PAGE resolving gel. 
For  running  western  blot  samples  the  resolving  gel  contained  8ml  protogel  (30% 
Acrylamide: 0.8% Bis-Acrylamide stock 37.5:1) (National Diagnostics, UK), 7.5ml 4x 
resolving gel buffer, 15ml distilled H20, 100µl of 10% APS (w/v) (Biorad, Germany) 
and 20µl TEMED (Biorad, Germany). 
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2.2.5 SDS-acrylamide SDS-PAGE stacking gel. 
For running western blot samples the stacking gel contained 1.6ml protogel (National 
Diagnostics, UK), 3.1ml 4x stacking gel buffer, 7.6ml distilled H20, 62.5µl of 10% APS 
(w/v) (Biorad, Germany) and 12.5µl TEMED (Biorad, Germany). 
 
2.2.6 4x SDS-PAGE loading buffer. 
The  loading  buffer  for  Western  blot  samples  contained  0.454g  TRIS  pH6.8  (Sigma, 
USA),  15µl  20%SDS  (Biorad,  Germany),  4.8ml  Glycerol  (Sigma,  USA),  3ml  2-
mercaptoethanol  (Sigma,  USA),  0.5g  Bromophenol  Blue  (Sigma,  USA)  and  30ml 
distilled H20.  
 
2.2.7 10x Running buffer. 
The  Western  blot  running  buffer  was  purchased  as  10x  TRIS/Glycine/SDS  running 
buffer (Biorad, Germany). 
 
2.2.8 10x Transfer buffer. 
The  Western  blot  transfer  buffer  was  made  from  44.26g  CAPS  (100mM)  (3-
[Cyclohexylamino]-1-propanesulfonic acid) (Sigma, USA) in 2L distilled H20 and the 
pH was adjusted to 11 with NaOH. 
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2.2.9 Stripping buffer. 
The Western blot stripping buffer contained 3.9ml 2-mercaptoethonol (Sigma, USA), 
100ml 10% SDS (Biorad, Germany), 31.25ml 1M Tris pH6.7 (Sigma, USA) in 500ml 
distilled H20. 
 
2.2.10 Western blot wash buffer. 
The Western blot wash buffer contained 1xPBS (media kitchen, NIMR, UK) and 0.5% 
TWEEN 20 (Sigma, USA) 
 
2.2.10 Western blot blocking solution. 
The Western blot blocking solution was made from 5% (w/v) dry milk powder (Western 
Laboratory Supplies, UK) dissolved in western blot wash buffer. 
 
2.2.11 Development substrate. 
The Western blot development substrate was purchased and mixed at an equal ratio of 
LumiGlo substrate A and LumiGlo substrate B (KPL, USA). 
 
2.2.12 ELISA wash buffer. 
The ELISA wash buffer was made from 1xPBS (media kitchen, NIMR, UK) and 0.25% 
TWEEN 20 (Sigma, USA). 
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2.2.13 ELISA substrates. 
ELISA substrate a) was ABTS made from 0.15g ABTS (2,2’-Azino-bis(3-Ethylbenz-
Thiazoline-6-sulfonic Acid)) (Sigma, USA), 0.1M citric acid (Fisher Scientific, UK) and 
the pH was adjusted to 4.35 with NaOH. 2µl peroxide/10ml (Sigma, USA) was added 
before use. 
ELISA substrate b) was purchased as TMB (E-biosciences, UK). 
 
2.2.14 ELISA stop solutions. 
Stop solution a) contained 1.25% (w/v) Sodium fluoride dissolved in H20 (Sigma, USA) 
for ABTS and stop solution b) contained 2N H2SO4 (Signa, USA) for TMB. 
 
2.2.15 Ear punch buffer for digestion of mouse tissue. 
Buffer for digestion of mouse tissue contained 50mM TRIS pH 8 (Sigma, USA), 2mM 
NaCl  (Sigma,  USA),  10mM  EDTA  pH  8  (Sigma,  USA),  1%  (v/v)  SDS  (Biorad, 
Germany) and 1mg/ml Proteinase K (Roche Diagnostics, Germany). 
 
2.2.16 DNA precipitation. 
For DNA precipitation 1/10 sample volume 3M NaAc pH 5.2 was mixed with 2x sample 
volume100% Ethanol (Fisher Scientific, UK) and added to the sample. 
 
2.2.17 PCR mix. 
PCR reactions contained 2.5µl 10x PCR buffer (ABgene, UK), 2.5 µl 25mM MgCl2  
(ABgene, UK), 0.5µl 10mM dNTPs (ABgene, UK), 0.5µl Primer A, 0.5µl Primer B,   67 
0.5µl Primer C, 0.2µl  5U/µl Taq polymerase (ABgene, UK), 15.8µl H20 and 2µl sample 
DNA. 
 
2.2.18 2% Agarose gel. 
Agarose gel contained 4g Agarose (Biorad, Germany) mixed with 200ml 1x TBE buffer 
(Media kitchen, NIMR, UK) and 15µl Ethidium bromide (Biorad, Germany). 
 
2.2.19 DNA 5x loading buffer. 
The loading buffer for DNA samples contained 0.4% (w/v) Bromophenol blue (Sigma, 
USA), 0.4% (w/v) Xylene Cyanol (Sigma, USA), 25ml Glycerol (Sigma, USA) made up 
in 25ml H20. 
 
2.2.20 Formalin. 
Formalin  for  tissue  fixing  contained  100ml  formaldehyde  (Sigma,  USA),  8.2g  NaCl 
(Sigma, USA) made up in 900ml H20. 
 
2.3 Medium 
 
2.3.1 Complete RPMI. 
Tissue  culture  medium  used  for  generation  of  all  cells  contained  RPMI    (Cambrex, 
Belgium),  5%  heat-inactivated  foetal  calf  serum  (FCS)  (Labtech,  USA),  1%  L-
Glutamine  (Cambrex,  Belgium),  1%  penicillin/streptomycin  (Pen/Strep)(Cambrex,   68 
Belgium), 1% HEPES (Cambrex, Belgium), 1% Sodium-pyruvate (Cambrex, Belgium) 
and 0.1M 2-mercaptoethanol (Sigma, USA) 
 
2.3.2 PBS. 
Calcium  and  magnesium  free  endotoxin  free  phosphate  buffered  saline  (PBS)  was 
purchased from Gibco, UK. 
 
2.3.3 Sorting buffer. 
For cell sorting 500ml PBS (Gibco, UK), 5ml Pen/Strep (Cambrex, Belgium), 0.2mM 
EDTA (Cambrex Belgium) and 5ml FCS (Labtech, USA) was mixed. 
 
2.4 Equipment 
 
2.4.1 Western blot. 
Equipment used for Western blot included Hoefer SE 400 vertical unit (Amersham, UK) 
for casting and running gels, Transblot unit (Biorad, Germany) for transferring protein, 
Power  pack  E865  (Consort,  USA)  for  all  electrical  output,  Bio-spec-mini 
spectrophotometer  (Shimadzu,  UK),  PDVF  transfer  membranes  (Millipore,  USA), 
18x24cm Film cassette (Kodak, UK), 18x24cm X-ograph film (Kodak, UK) and Film 
developer (Fuji Film). 
 
2.4.2 ELISA. 
The ELISA reader was a Multiscan Ex (Labsystems, UK)   69 
 
2.4.3 PCR and electrophoresis. 
Equipment used for PCR included PCR machine GeneAmp PCR system 2700 (Applied 
Biosciences, USA), Thermo EC Maxicell Primo gel running tank (USA) and UV DNA 
transilluminator (BioDoc-it system, USA). 
 
2.4.4 Real-time PCR. 
ABI Prism 7000 detection system (Applied Biosciences, USA) was used for real-time 
PCR quantification. 
 
2.4.5 Cell culture. 
Equipment used during cell culture included Hera Cell incubator (Heraeus, UK) and a 
Haemocytometer for cell counting. 
 
2.4.6 Cell sorter. 
Equipment used for cell sorting included AutoMACS (Milteney, Germany) and MoFlo 
Cell sorter (Cytomation, USA). 
 
2.4.7 Computer programs. 
All graphs were illustrated using Prism 4 (Graphpad software). Calculations of RT-PCR 
results were done using Excel (Microsoft). All text was typed using Word (Microsoft). 
All western blots were scanned into an image processing software (Arcsoft Photostudio) 
and copied into Powerpoint (Microsoft).   70 
 
2.5 Reagents and antibodies 
 
2.5.1 Western blot antibodies and reagents. 
Phospho-p38 (9215), total-p38 (9212), and total-JNK (9252) were purchased from Cell 
Signaling, USA and used at 1:1000. Phospho-ERK (44-680G) and phospho-JNK (44-
682G) were from Biosource, USA and used at 1:1000. Anti-ERK16 was a gift from 
Jeremy Tavaré (University of Bristol) and used at 1:10000. Anti-Tpl-2 antibody (sc-720) 
and anti-IκBα antibody (sc-1643) were purchased from Santa Cruz, USA and used at 
1:1000. α-Actin antibody (sc-58670) was from Oncogene, USA and used at 1:10000. 
HRP-conjugated  anti-mouse  IgG  (1021-05)  and  anti-rabbit  IgG  (4020-05)  were 
purchased from Southern Biotechnology, USA and used at 1:10000. 5x Protein dye for 
Bradford assay was from Biorad, Germany and the Rainbow protein marker was from 
Amersham, UK. 
 
2.5.2 ELISA. 
IL-12p70 and TNF ELISA kits were purchased from e-biosciences, UK. IL-10 and IL-
12p40 ELISA antibodies were purchased from Pharmingen, USA. IFN-β ELISA kit was 
from PBL Biomedical Laboratories, USA. 
 
2.5.3 Antibodies for cell sorting. 
Anti-CD11c-PE and Anti-FcR III/II were purchased from BD, USA. CD11c microbeads 
was from Milterney, Germany.   71 
 
2.5.4 PCR Primer sequences. 
Tpl-2 A: 5’ CTT CAG TCA TCT TAA CAC TCA GGC 3’ 
Tpl-2 B: 5’ CTG CTT GGA ACT TGC TGT TCT AGA TG 3’ 
Tpl-2 C: 5’ CTG CAC GAG ACT AGT GAG ACG TGC 3’ 
IL-10 T1.4: 5’ GCC TTC AGT ATA AAA GGG GGA CC 3’ 
IL-10 T2.2: 5’ GTG GGT GCA GTT ATT GTC TTC CCG 3’ 
Neo 5: 5’ CCT GCG TGC AAT CCA TCT TG 3’ 
All primes were supplied by Eurogentec (UK) 
 
2.5.5 Real-time PCR Primer sequences. 
IL-10: 5’ TTT GAA TTC CCT GGG TGA GAA 3’ 
           3’ GCT CCA CTG CCT TGC TCT TAT T 5’ 
IL-12p40: 5’ CAA ATT ACT CCG GAC GGT TCA 3’ 
        3’ AGA GAC GCC ATT CCA CAT GCT 5’ 
IL-12p35: 5’ CCT GCA CTG AAG ACA TC 3’ 
       3’ GCT CCC TCT TGT GGA AG 5’ 
TNF: 5’ GCC ACC ACG CTC TTC TGT CT 3’ 
          3’ TGA GGG TCT GGG CCA TAG AAC 5’ 
IFN-β: 5’ GCA CTG GGT GGA AGT AGA CT 3’ 
            3’ AGT GGA GAG CAG TTG AGG ACA 5’ 
Ubiquitin: 5’ TGG CTA TTA ATT ATT CGG TCT GCA T 3’ 
       3’ GCA AGT GGC TAG AGT GCA GAG TAA 5’   72 
All supplied by Eurogentec (UK) 
 
2.5.6 CpG 1668 sequence. 
5’ TCC ATG ACG TTC CTG ATG CT 3’ all bases are on a phosphorothioate backbone 
(InVitrogen, UK) 
 
2.5.7 Real-time PCR. 
Fluorescent DNA binding dye SYBR Green was purchased from Applied Biosciences, 
USA. 
 
2.5.8 Other reagents. 
U0126 MEK inhibitor was purchased from Biomol (USA), Lipopolysaccharide (LPS) 
was  from  Alexis,  Canada,  DMSO  (Dimethyl  sulfoxide  99.5%)  was  purchased  from 
Sigma, USA, Granulocyte-macrophage stimulating factor (GM-CSF) was from DNAX, 
USA, Macrophage stimulating factor (M-CSF) containing L-cell supernatant was made 
at the large scale lab (NIMR, UK). Liberase Cl was purchased from Roche Diagnostics, 
Germany and 0.83% Ammonium Chloride was from the Media kitchen (NIMR, UK) 
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2.6 Mice 
 
2.6.1 C57BL/6 mice. 
C57BL/6 mice were bred under pathogen free conditions at the NIMR (UK). All animals 
were sacrificed according to regulated procedures (Schedule 1). The mice were between 
8-12 weeks of age. 
 
2.6.2 IL-10
-/- mice. 
IL-10
-/- mice on the C57BL/6 background bred under pathogen free conditions at the 
NIMR (UK). The mice have been backcrossed to C57BL/6 for 10 generations. 
 
2.6.3 Tpl-2
-/- mice. 
Tpl-2
-/- mice on the C57BL/6 background were a kind gift from Phillip Tsichlis (Tufts 
University,  USA).  As  the  mice  were  only  backcrossed  to  the  6
th  generation,  we 
continued  to  breed  to  the  mice  as  heterozygous crossing  and  were  screening  all  the 
offspring. The mice were bred in a quarantine unit at NIMR (UK). 
 
2.6.4 Tpl-2
-/-/IL-10
-/- mice. 
Tpl-2
-/-/IL-10
-/- mice were generated by intercrossing the Tpl-2
-/- mouse to an IL-10
-/- 
mouse. The offspring was screened and crossed to generate 4 genotypes: wildtype, Tpl-
2
-/-, IL-10
-/- and Tpl-2
-/-/IL-10
-/- mice. These mice were bred in a quarantine unit at NIMR 
(UK). 
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2.7 Genotyping of mice. 
 
When the mice were weaned a small piece of the ear was collected. The tissue was 
digested in earpunch buffer at 56°C overnight.  The proteinase K was inactivated by 
boiling  for  3  minutes.  The  DNA  was  precipited  at  -20°C  overnight.  Next  day  the 
samples were spun down (13000 rpm for 30min at 4°C) and the supernatant removed. 
The  precipitate  was  left  to  dry  at  room  temperature  for  10  minutes  before  being 
resuspended in water. Amplification of the DNA was carried out by PCR.  
The amplification cycles for identification of the Tpl-2 genotype was: 
94°C for 7 minutes 
94°C for 45 seconds 
52°C for 45 seconds 
72°C for 45 seconds  
72°C for 7 minutes 
 
The amplification cycles for identification of the IL-10 genotype was: 
94°C for 7 minutes 
94°C for 1 minute 
60°C for 1 minute 
72°C for 1 minute  
72°C for 7 minutes 
 
35 cycles 
30 cycles   75 
The DNA was run on an agarose gel containing Ethidium bromide until separation of the 
DNA was visible under UV light.  
 
2.8 Generation of myeloid dendritic cells. 
 
Myeloid  dendritic  cells  were  generated  according  to  the  original  protocol  by  Inaba 
(Inaba et al. 1992). In brief, femurs and tibiae from mice were flushed with complete 
RPMI. Red blood cells were lysed with ammonium-chloride for 2 min. Cells were plated 
out in 6-well plates at 1x10
6 cells/ml in medium containing 10ng/ml GM-CSF. On day 2, 
non-adherent cells were removed, cells gently washed and fresh medium supplemented 
with GM-CSF added. This was repeated on day 4 omitting the wash step. On day 6, non-
adherent  cells  were  collected  and  replated  in  tissue  culture  at  0.5x10
6  cells/ml  with 
medium containing GM-CSF. On day 7, non-adherent cells (DC) were harvested after 
16  hours  replating  and  used  as  required.  The  cells  generated  contained  a  70%  pure 
population of myeloid DC (CD11c
+) according to Flow cytometry analysis. However, if 
a greater purity was required, the cells were sorted for CD11c
+ using a MoFlo Cell 
sorter. The cell sorting was carried out by the FACS Lab (NIMR, UK). 
 
2.9 Generation of bone marrow derived macrophages. 
 
Femurs and tibiae were flushed and cells prepared as described in section 2.8. The cells 
were plated out at 4x10
6 cells/ml in petridishes in complete RPMI containing 20% L-cell 
supernatant. On day 4, cells were fed with 10ml complete RPMI containing 20% L-cell   76 
supernatant.  On day  7,  adherent cells were harvested with icecold PBS. Briefly, the 
supernatant was removed and replaced with 5ml icecold PBS and incubated at 4°C until 
the macrophages detached. 
 
2.10 Generation of splenic dendritic cells. 
 
Mouse spleens were collected and injected with 0.4mg/ml liberase Cl. After 30 min 
incubation at 37°C, the spleens were mashed though 70µm cell strainers and red blood 
cells were lysed with ammonium chloride. The cells were stained with 1µg/µl CD11c-
PE and incubated on CD11c microbeads for 30 min at 4°C, before being purified by 
AUTOMACS, which separates the labelled cells into CD11c
+ and CD11c
- fractions. 
After purification, the positive fraction was taking to the cell sorter, where it was further 
sorted for CD11c
+ using MoFlo Cell sorter. 
 
2.11 Cell stimulation 
 
2.11.1 Immunoassays. 
For cytokine immunoassays, 1x10
6 cells/ml were plated out in 24-well plates. The cells 
were stimulated with LPS or CpG at specified concentrations in presence or absence of 
MEK  inhibitor  U0126.  DMSO  was  used  as  vehicle  control.  The  supernatant  was 
collected after 1, 3, 6 and 20 hours and cytokines measured by ELISA.  
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2.11.2 Real-time quantitative PCR. 
For real-time quantitative PCR, the cells were plated out and stimulated as described in 
section 2.11.1. The cells were lysed and RNA purified using an RNeasy kit after 0, 1, 3 
and 6 hours of stimulation. 
 
2.11.3 Western blot. 
For Western blot, 1x10
6 cells/ml were plated out in 12-well plates and rested for 5 hours 
in  complete  RPMI  containing  1%  FCS  to  decrease  MAP  kinase  phosphorylation 
background signals. Cells were stimulated with the indicated concentrations LPS or CpG 
with or without inhibitor U0126. If the U0126 inhibitor was used, the cells were pre-
incubated with the inhibitor for 15 minutes prior to stimulation. 
 
2.12 Methods 
 
2.12.1 Western blot. 
Cells  were  lysed  in  RIPA  buffer,  and  the  protein  concentration  was checked  by  the 
Bradford  assay.  Briefly,  5x  dye  was  added  to  the  samples  and  the  wavelength  was 
measured at 595nm on a spectrophotometer. All protein samples were run on 8% SDS-
acrylamide  SDS-PAGE  gels.  The  proteins  were  transferred  overnight  to  a  PVDF 
membrane. The membranes were blocked in blocking solution. The membranes were 
probed with specific antibodies to the phosphorylated or constitutive form of the protein 
of intend. Proteins were visualised using the LumiGlo kit. Membrane were stripped at 
56°C for 20min before reprobing   78 
 
2.12.2 Real-time quantitative PCR. 
Total RNA was prepared and purified using Qiagen RNeasy minicolumn kit following 
the  manufacturers  protocol.  To  measure  the  relative  amount  of  cytokine  mRNA, 
amplification  of  cDNA  was  monitored  with  SYBR  Green  and  specific  primers  in 
combination with the ABI Prism 7000 detction system. Cytokine mRNA values were 
normalised to ubiquitin signals using the following formula was used: 1.8*(Ubiquitin 
value –Cytokine sample value)*100000 
 
2.12.3 ELISA. 
ELISA plates were coated with the capture antibody over night at 4°C. The plates were 
then  blocked  for  1  hour  with  FCS.  Samples  were  incubated  on  plates  for  2  hours. 
Detection antibody was added for 1 hr. Conjugated HRP was added for 1 hour and 
ELISA  was  developed  using  correct  substrate.  All  steps  were  carried  out  at  room 
temperature in a humidity chamber unless otherwise stated. Plates were washed 8 times 
in wash buffer between each step. 
 
2.12.4 Histology. 
Colon and caecum was removed from sacrificed mice and fixed in buffered formalin at 
room temperature over night. The histology procedure was carried by the NIMR 
histology department. Sections were cut from the colon and caecum and embedded in 
paraffin blocks. Sections were cut and stained with hematoxylin (H) and eosion (E) and 
fixed on slides. The sections were then visualised by light microscopy.   79 
 
Chapter 3 
Establishing the experimental system 
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3.1 Cytokine production in myeloid dendritic cells can be initiated at low doses of LPS 
and CpG. 
 
  Mouse myeloid DC and macrophages express TLR4 and TLR9 and thus respond 
to  their  respective  ligands,  LPS  and  CpG  (Akira  and  Takeda  2004).  However,  the 
optimal dose of these stimuli had not been established and doses of LPS range between 
100ng/ml  to  10µg/ml,  whereas,  CpG  was  used  at  1µM  in  published  studies.  We 
stimulated myeloid DC with LPS or CpG at increasing doses in order to find the optimal 
concentration for induction of the cytokines IL-10, IL-12p40/p70 and TNF (Figure 3.1).  
The LPS titration was initiated at 10µg/ml and titrated down to 6pg/ml. The CpG 
titration  was  initiated  at 1000nM,  a  concentration  used  in  the  literature,  and  titrated 
down to 0.5nM. As seen in Figure 3.1, the induction of cytokines started to titrate at 
doses of LPS doses below 10ng/ml and 60nM of CpG. Thus both LPS and CpG are 
normally  used  at  saturating  concentrations  at  which  subtle  modulation  of  cytokine 
production might not be detectable. Based on these titration curves, we selected the LPS 
dose of 10ng/ml and the CpG dose of 500nM for optimal stimulation of the production 
of cytokines, which was just at the beginning of the plateau (Figure 3.1) of cytokine 
induction. Dose response curves for induction of cytokines in macrophages were similar 
as compared to the dose response curves for myeloid DC. 
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3.2  Kinetics  of  LPS  and  CpG  for  cytokine  transcription  in  myeloid  DC  and 
macrophages. 
 
  The literature is very limited with information on the kinetics of induction of 
different  cytokines  with  different  TLR  ligands  in  myeloid  DC  and  macrophages, 
therefore we determined which time point was appropriate for optimal mRNA and  
cytokine  induction  after  stimulation  with  the  optimal  doses  of  LPS  or  CpG  in  both 
myeloid DC and macrophages. To do this, we set up a time course of stimulation with 
LPS and CpG and collected total RNA at 0, 1, 3, and 6 hours. Tnf, Il-10, Il-12p40, and 
Il-12p35 mRNA were measured by real-time quantitative PCR (Figure 3.2). 
As shown in Figure 3.2, induction of Tnf mRNA peaked early at 3 hours in both 
myeloid DC and macrophages. Il-10 mRNA induction had  different kinetics in DC and 
macrophages. Following LPS or CpG stimulation of DC, Il-10 mRNA induction peaked 
late at 6 hours, whereas in macrophages IL-10 mRNA peaked at 1 hour. Induction of Il-
12p40 mRNA was also different between DC and macrophages. LPS or CpG stimulation 
of DC induced maximal Il-12p40 mRNA at 6 hours, whereas in macrophages Il-12p40 
mRNA peaked earlier at 3 hours. Induction of Il-12p35 mRNA was only detectable in 
DC and after both LPS or CpG stimulation peaked between 3 to 6 hours. It was therefore 
not  possible  to  select  a  single  time  point  for  LPS  or  CpG  stimulation.  In  future 
experiments we decided to continue to perform a time course in order to allow for the 
differences in the kinetics and to ensure that subtle changes in the induction of any of the 
cytokines could be observed.   82 
3.3 Kinetics of cytokine protein production in myeloid DC and macrophages. 
 
  Having  investigated  the  kinetics  of  mRNA  induction,  we  investigated  the 
kinetics for cytokine protein production. To do this, myeloid DC and macrophages were 
stimulated with LPS or CpG for 0, 3, 6, 20, and 48 hours and the supernatants were 
collected and assayed for cytokines by immunoassay (Figure 3.3). 
LPS and CpG followed the same kinetics for induction of IL-10 and IL-12p40 
production in the myeloid DC, reaching a plateau at 20 hours. TNF, however, reached a  
plateau at 6 hours where it remained for CpG, but peaked around 20 hours for LPS and 
then dropped off (Figure 3.3a).  
Similarly in macrophages (Figure 3.3b) stimulated with LPS, the IL-10 and IL-
12p40  protein  levels  reached  a  plateau  at  20  hours  and  TNF  at  6  hours  and  were 
sustained. The CpG kinetics in macrophages were a bit different from LPS, as both IL-
10 and IL-12p40 did not reach a plateau during the time course, but kept on increasing 
up to 48 hours upon stimulation with LPS. TNF reached a plateau at 6 hours. Taking all 
the cytokine data into account, we decided that the optimal stimulation times were 20 
hours for IL-10 and IL-12 protein induction and 6 hours for TNF protein induction for 
both myeloid DC and macrophages stimulated with LPS or CpG. 
 
3.4 Kinetics of activation of MAP kinases by LPS and CpG. 
 
  Interested in determining the role of ERK in regulating cytokine production as it 
has been reported that LPS or CpG cannot induce ERK phosphorylation in myeloid DC,   83 
although in the same report both LPS and CpG induced ERK phosphorylation in a RAW 
macrophage cell line and peritoneal macrophages (Hacker  et al. 1999). However, in 
another study , it has been shown that LPS can induce phosphorylation of ERK in DC 
(Dillon et al. 2004). We investigated the kinetics for MAP kinase activation in detail in 
the myeloid DC following stimulation with LPS and CpG (Figure 3.4), using phospho-
specific ERK and p38 antibodies as a readout for MAP kinase activation.  
Myeloid DC were stimulated with either LPS or CpG for 0, 7.5, 15, 30, 45, and 
60 minutes. Lysates were then immunoblotted for phosphorylated and total forms of p-
38, ERK and total IκBα. As seen in Figure 3.4, LPS induced phosphorylation of ERK 
and p38 after only 7.5 minutes. After 45 minutes the signal started to weaken. CpG 
showed a much slower kinetics of induction of ERK phosphorylation. Only after 30 
minutes  of  stimulation  was  it  possible  to  detect  a  signal  for  ERK  and  p38 
phosphorylation. After 60 minutes however, the signal weakened. 
 
3.5  Stimulation  of  myeloid  DC  with  LPS  and  CpG  can  induce  MAP  kinase 
phosphorylation even at low concentrations. 
 
  The  concentrations  of  LPS  and  CpG  required  to  induce  MAP  kinase 
phosphorylation, which have been used in the literature range from 1µg/ml to 10µg/ml 
LPS and on average of 1µM for CpG. We wished to determine the optimal dose of each 
of these stimuli to ensure the signal induced was on the plateau but at a level at which 
one could still detect subtle differences in signal strength. Figure 3.5a shows that high 
doses  of  both  LPS  (0.5-100ng/ml)  and  CpG  (50-1000nM)  potently  activated  MAP   84 
kinase phosphorylation as detected by immunoblotting. Figure 3.5b shows that the ERK 
phosphorylation was observed at 500pg/ml LPS but was not detectable at 50pg/ml and 
that  the  CpG  induced  ERK  phosphorylation  could  still  be  observed  down  to  a 
concentration of 50nM  below which the signal was lost.  Interestingly these findings 
reflect the cytokine assay results (Figure 3.1), where LPS started to titrate out between 
10ng/ml and 1ng/ml and however, CpG titrated out between 60 and 250nM. However, 
for  both  LPS  and  CpG  stimulation,  IκBα  degradation  was  only  induced  at  higher 
concentrations of stimuli. For LPS, IκBα degradation can be detected at doses above 
500pg/ml and for CpG above 100nM. Taken together with the cytokine titration curves 
(Figure 3.1), we chose 10ng/ml LPS and 500nM CpG for all future assays to ensure a 
signal that could reveal any modulation in subsequent experiments. 
 
3.6 Discussion. 
 
  Based on the titration experiments in this section, we were able to select the 
optimal  dose  of  LPS  and  CpG  for  stimulation of  myeloid  DC  and  macrophages  for 
production of cytokines and activation of ERK and p38 MAP kinases (Figure 3.1 and 
3.5). We chose to use 10ng/ml LPS and 500nM CpG, as these doses were sufficient to 
induce clear phosphorylation of both MAP kinases and where such concentrations were 
at the beginning of the plateau for induction of cytokine production. Such concentrations 
were predicted to be at a level that could allow observation of subtle changes in cytokine 
production resulting from interference with specific MAP kinase signalling pathways.   85 
  Kinetic analysis of cytokine mRNA expression by real-time quantitative PCR 
showed that the peak time point for Tnf mRNA was 3 hours and for Il-10, Il-12p40 and 
Il-12p35  mRNA  was  6  hours  for  both  DC  and  macrophages.  However,  due  to 
differences between macrophages and DC in the rate of induction or Il-10 and Il-12p40 
mRNA, we concluded that a full time course of stimulation would be necessary  for 
subsequent experiments (Figure 3.2). For kinetic experiments assaying cytokine protein 
production, 20 hours was chosen as the optimal time to assay IL-10, IL-12p40 and IL-
12p70, whereas TNF, which peaked earlier, was assayed at 6 hours (Figure 3.3). The 
immunoassays measure the accumulation of the cytokine in the supernatant. During the 
kinetics  experiment,  we  collected  the  supernatant  at  the  described  times  without 
replacing the medium. Upon TLR stimulation the cell signalling cascade will become 
activated leading to the transcription of cytokines. As seen in Figure 3.2, this can be 
detected by quantitative PCR as soon as 1 hour of stimulation (peak times are dependent 
on  the  cytokine).  After  cytokine  mRNA  transcription  takes  place,  translation  and 
eventually  production  and  secretion  of  the  soluble  protein  can  be  detected  by 
immunoassay. The soluble cytokines are released into the culture medium, where they 
can interact with their cytokine receptor on the cells in the medium signalling into the 
cell and potentially influencing the production of cytokines in the local environment. For 
example, IL-10 produced by macrophages and DC can affect the production of IL-12 by 
the same cell population by negatively regulating its production. Therefore, at each time 
point it is only possible to measure the accumulated cytokines in the medium and not 
quantify the exact production due to absorption and even degradation of the proteins. 
For example, IL-2 production by T cells is often difficult to measure accurately since IL-  86 
2 is a growth factor for T cells and is readily consumed. To overcome this issue and 
measure  IL-2  protein  in  the  supernatants  of  activated  T  cells  accurately  anti-IL-2 
receptor antibodies have been used to block the IL-2 consumption (Meuer et al. 1984). 
Thus far this does not appear to be a major issue in measuring cytokine production in 
DC and macrophages. To support this in our experiments (Figure 3.3) we show that the 
cytokines measured increased with time after stimulation all reached a plateau and that 
this plateau was maintained over time, which suggests that they are not consumed or 
degraded and therefore blocking the various cytokine receptors does not seem necessary. 
 Myeloid DC stimulated with LPS resulted in phosphorylation of ERK and p38 
after 7.5 minutes, however following stimulation with CpG stimulation phosphorylation 
of ERK and p38 was observed after 30 minutes (Figure 3.4). We therefore picked 15 
minutes for LPS and 30 minutes for CpG for subsequent experiments, as the signals 
detected were strongest at these time points. 
  In a previous study, it was suggested that neither LPS or CpG could induce ERK 
phosphorylation in bone marrow derived myeloid DC although these stimuli induced 
ERK phosphorylation in a macrophage cell line and in peritoneal macrophages (Hacker 
et al. 1999). Our data does not support the findings of Hacker et al. (1999). We found 
that LPS and CpG were potent in inducing MAP kinase phosphorylation in macrophages 
and myeloid DC, although the kinetics of activation were different between LPS and 
CpG. This could be due to the fact that CpG has to be internalised first before signalling 
can be initiated (Krieg 2002). A reason for these differences between our results and 
those of Hacker et al. (1999) could be due to high the background in their immunoblot 
which could mask subtle changes in ERK phosphorylation. To overcome issues with   87 
high background, we rest our cells for 5 hours in medium containing low serum, before 
the cells are stimulated, which allows observation of the lower levels of phosphorylation 
of MAP kinases observed in primary cells opposed to cell lines. Consistent with our 
findings, studies using human monocyte derived DC or murine splenic DC found that 
LPS induced ERK phosphorylation in both these DC populations (Agrawal et al. 2003; 
Dillon et al. 2004) 
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Figure 3.1. Titration of LPS and CpG for cytokine induction in myeloid DC. LPS 
was titrated from 10000ng/ml to 6pg/ml and CpG from 1000nM to 0.5nM. Cytokine 
production was measured by ELISA after 20 hours stimulation. The detection limits 
were: TNF 50pg/ml, IL-10 75pg/ml, IL-12p40 50pg/ml, and IL-12p70 50pg/ml. 
Triplicate points were tested for each experiment. Results are representative of three 
similar experiments.  
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Figure 3.2: Kinetics of induction of cytokine mRNA in myeloid DC and 
macrophages.  a) Myeloid DC or b) macrophages were stimulated with LPS or 
CpG for the specified times before RNA was purified. Cytokine transcription was 
checked by real-time quantitative PCR. Triplicate points were tested for each 
experiment. Results are representative of three similar experiments.   91 
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Figure 3.3: Kinetics of LPS and CpG for cytokine protein induction in 
myeloid DC and macrophages. a) Myeloid DC and b) macrophages were 
stimulated between 0 and 48 hours LPS or CpG. Supernatants were collected at the 
indicated times. Triplicate points were tested for each experiment. Results are 
representative of three similar experiments.   92 
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Figure 3.4: LPS activates ERK and p38 with more rapid kinetics than CpG 
in myeloid DC. Myeloid DC were stimulated with LPS or CpG for the specified 
time and lysates were immunoblotted for phosphorylated and total form of ERK 
and p38. LPS and CpG were run on the same gel. Representative of 3 
experiments. 
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Figure 3.5. Dose response for ERK phosphorylation by LPS or CpG in 
myeloid DC. Myeloid DC were stimulated with LPS for 15min and CpG for 
30min and lysates immunoblotted for the indicated kinases. LPS and CpG 
were run on separate gels. Exposure times for each antibody was 
approximately the same between LPS and CpG. Representative of 3 
experiments. 
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Establishment of specificity of different methods to inhibit 
downstream ERK phosphorylation   95 
4.1 Background. 
 
We used pharmacological and genetic methodologies to investigate the role of 
ERK  in  regulating  TLR  induction  of  cytokine  production.  First,  we  used  a  MEK 
inhibitor  U0126,  which has  been  reported  to  selectively  block  ERK  phosphorylation 
(Favata et al. 1998). Secondly we used cells from a Tpl-2 deficient mouse strain, which 
has been shown to be deficient in ERK activation but not in the activation of other MAP 
kinase after LPS stimulation of macrophages (Dumitru et al. 2000).  
 
4.2 Specificity of MEK inhibitor U0126. 
 
  As the focus of this project was to determine the effects of ERK phosphorylation 
on cytokine production, we first determined whether the MEK inhibitor U0126 could 
block  ERK  phosphorylation  without  affecting  the  activation  of  other  MAP  kinases. 
Myeloid DC were stimulated with different doses of LPS and CpG in the presence or 
absence of U0126. We initially tested the inhibitor at 10µM against titrations of LPS and 
CpG, since this dose has been broadly used in the literature (Figure 4.2).  
  In Figure 4.2, it can be seen that the U0126 inhibitor effectively inhibited ERK 
phosphorylation  at  both  high  and  low  doses  of  stimuli  in  myeloid  DC.  However, 
phosphorylation of p38  was also affected at this dose of the U0126 MEK inhibitor, 
which was very clear for stimulations with CpG although less so with LPS. 
   96 
4.3 The inhibitory effect of 10µM U0126 on LPS and CpG induced p38 phosphorylation 
in macrophages and myeloid DC may be due to non-specific effects of the inhibitor 
. 
  Due to U0126 affecting both the p38 and ERK pathways when used at 10µM, we 
titrated the inhibitor on myeloid DC and macrophages stimulated with 10ng/ml LPS or 
500nM  CpG  to  determine,  whether  lower  doses  of  U0126  inhibited  ERK 
phosphorylation specifically (Figure 4.3). The titration was started at 5µM and taken 
down to 0.3µM. U0126 completely inhibited stimulus-induced phosphorylation of ERK 
when used at doses as low as 0.3-0.6µM. However, doses below 5µM of U0126 did not 
appear to show any inhibition of the induction of p38 or JNK in either myeloid DC and 
macrophages stimulated with LPS or CpG.  
 
4.4 Cell surface phenotype of immune cells in the Tpl-2 knock-out mouse. 
 
  The Tpl-2 knock-out mouse was generated by disruption of the Tpl-2 gene in 
embryonic stem cells by homologous recombination leading to deletion of a portion of 
the Tpl-2 catalytic domain including the ATP binding site and activation loop (Dumitru 
et al. 2000). The Tpl-2 knock-out mice were kept and bred in a quarantine unit. Some of 
the Tpl-2 deficient mice were kept up until 7 months of age, during which they did not 
display any physical signs of illness when compared to littermate controls. They also 
bred equally well as compared to littermate controls.  
  To ensure that the development of the immune system was normal, spleen and 
lymph  nodes  were  collected  from  three  Tpl-2  deficient,  three  heterozygous  and   97 
compared to wild type control mice by flow cytometric analysis. The cells were stained 
with markers for DC (CD11b, CD11c, 120G8), macrophages (CD11b, F4/80), T cells 
(CD4
+, CD8
+) and CD44 (memory marker), CD69 (T cell activation marker) and CD4
+ 
CD25 (T reg marker on the T cells), B cells (CD19) and analysed by flow cytometry. 
The staining and analysis was carried out by another lab member, Rute Marques. The 
FACS analysis showed that the percentage and total numbers of DC and macrophages 
were the same in all the phenotypes. The ratio of T cells to DC, T cells to B cells, and 
CD4
+ to CD8
+ in the Tpl-2 deficient mouse were the same and did not differ from the 
wild type controls. Numbers and percentages of CD44, CD69 and CD25 positive cells 
were also the same in the Tpl-2
-/- versus the wildtype control mice. In summary there is 
no difference between the wild type, heterozygous and Tpl-2 deficient mice in terms of 
cell numbers and cell percentages of DC, macrophages, T cells or B cells. 
  Expression of TLR4 and TLR9 levels was not checked. This was due to the 
difficulty in finding an appropriate antibody at the time to quantify the levels of TLR 
expression.    TLR4  is  a  surface  receptor,  whereas,  TLR9  is  an  intracellular  receptor 
(Krieg 2002; Yasuda et al. 2006). It is possible to determine levels of mRNA expression 
of  TLR4  and  TLR9,  however,  since  mRNA  may  not  reflect  the  protein  levels  post 
transcriptionally versus post translationally we did not use this strategy. We however, 
found that the activation of MAP kinase JNK activated by LPS or CpG was the same in 
the Tpl-2 deficient macrophages and myeloid DC as compared to the wildtype controls 
(Figure 4.5), supporting that the level of TLR expression  on macrophages and DC may 
not be altered  and thus the same level in the Tpl-2 knock-out mouse as compared to the 
wildtype controls.   98 
 
4.5 ERK phosphorylation is blocked and p38 phosphorylation is reduced in the absence 
of Tpl-2. 
 
  It  has  been  shown  that  LPS  does  not  activate  ERK  in  Tpl-2  deficient 
macrophages,  but  phosphorylation  of  JNK  and  p38  were  unaffected  (Dumitru  et  al. 
2000). However, another report suggested that CpG could still induce phosphorylation 
of ERK in Tpl-2 deficient macrophages (Sugimoto et al. 2004), suggesting that TLR9 
does not utilise Tpl-2 to activate ERK. Our results confirmed that LPS does not activate 
ERK in Tpl-2 deficient macrophages. However, we also found that CpG activation of 
ERK was blocked in Tpl-2 deficient macrophages (Figure 4.5). We also showed that 
neither LPS nor CpG in the absence of Tpl-2 could activate ERK phosphorylation in 
myeloid DC (Figure 4.5). Our findings are in contrast to those of Sugimoto et al. (2004). 
We observed decreased induction of p38 phosphorylation in Tpl-2 knockout cells 
following TLR stimulation of both macrophages and myeloid DC. In macrophages this 
inhibitory effect on p38 phosphorylation was most pronounced after CpG stimulation 
and less prominent after LPS stimulation. However, p38 phosphorylation following both 
LPS and CpG stimulation in myeloid DC was clearly reduced in the absence of Tpl-2. 
Little or no effect was seen on the induction of phosphorylation of JNK by LPS or CpG 
in either Tpl-2 deficient macrophages or myeloid DC. 
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4.6 Discussion.  
 
We found that the commonly used concentration of U0126 inhibitor at 10µM 
affected  not  just  ERK  phosphorylation  but  also  p38  phosphorylation  (Figure  4.2)  in 
myeloid  DC,  which  we  thought  might  be  the  result  of  non-specific  effects  of  the 
inhibitor. Therefore, we titrated the U0126 inhibitor on both macrophages and myeloid 
DC  and  found  that  doses  between  5  and  0.6µM  acted  specifically  to  inhibit  ERK 
phosphorylation without affecting other MAP kinase pathways (Figure 4.3). Based upon 
the titration experiments on both MAP kinase activation and also cytokine induction, we 
chose to use the inhibitor at a dose of 2.5µM for our future studies, which did not affect 
p38  or  JNK  phosphorylation  and  thus  appeared  to  specifically  inhibit  ERK 
phosphorylation. 
We have also shown that Tpl-2 can affect p38 phosphorylation, which is more 
pronounced in macrophages stimulated with CpG than with LPS. Indeed effects on p38 
phosphorylation in the Tpl-2 deficient macrophages stimulated with LPS are only slight 
(Figure 4.5), which may explain why they were not noticed in the study by Dumitru et 
al. (2000). However, the requirement for Tpl-2 for maximal p38 phosphorylation was 
marked in myeloid DC stimulated with either LPS or CpG. An explanation for why p38 
phoshorylation is not affected in the Dumitru et al. (2000) study could be that they use 
peritoneal macrophages stimulated with 1µg/ml LPS. Since they use high concentrations 
of LPS and we have shown the effects on p38 phosphorylation is slight it is possible that 
it is for these reasons they have failed to observe any effect on p38 phosphorylation in 
the Tpl-2 deficient cells.   100 
  In  a  previous  study,  it  was  found  that  Tpl-2  deficiency  only  impaired  ERK 
phosphorylation  in  macrophages  stimulated  with  LPS  but  not  CpG  (Sugimoto  et  al. 
2004). This is sharp contrast to our findings (Figure 4.5), where we show that ERK 
phosphorylation  is  blocked  after  both  LPS  and  CpG  stimulation  in  Tpl-2  deficient 
macrophages and myeloid DC. One possible explanation for this discrepancy could be 
that the Tpl-2 deficient mice we used were generated in a different lab, although both 
mice show lack of the Tpl-2 kinase. Another explanation could be that the CpG used in 
the Sugimoto et al. (2004) study may be contaminated with a TLR independent ligand, 
which is responsible for the residual ERK phosphorylation. We test all CpG stocks for 
purity on TLR9 and MyD88 deficient mice and also confirm that no effects are observed 
in the TLR4 deficient mice to rule out endotoxin contamination to avoid this concern 
and can therefore vouch for the purity and specificity of CpG in our system. 
  We have shown that Tpl-2 may activate p38 as well as its target ERK upon 
stimulation of macrophages and particularly myeloid DC with LPS and CpG. We also 
saw this effect on p38 phosphorylation in myeloid DC stimulated with LPS or CpG in 
the presence of MEK inhibitor U0126 used at doses above 5µM. An explanation for the 
differences observed between the specificity on the inhibition ERK phosphorylation 
using U0126 or deletion of Tpl-2 could be that lack of Tpl-2 completely inhibits the 
activation of MEK, which inhibits the activation of ERK. In cells treated with U0126, 
both Tpl-2 and MEK are activated, but phosphorylation of ERK by MEK is blocked. 
Therefore, the effects of the abrogation Tpl-2 pathway may be more dramatic since Tpl-
2, MEK and ERK phosphorylation are both inhibited and in some cases p38 
phosphorylation is affected.   101 
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Figure 4.2: 10µM MEK inhibitor U0126 inhibits LPS and CpG induced ERK 
and p38 phosphorylation in myeloid DC. Myeloid DC were stimulated with LPS 
and CpG at the given concentrations in the presence or absence of 10µM U0126. 
Lysates were immunoblotted for the indicated antigens. LPS and CpG were run on 
separate gels. Exposure times are approximately the same for both LPS and CpG. 
Representative of 3 experiments. 
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Figure 4.3: Low doses of U0126 inhibit LPS and CpG induced ERK but not 
p38 phosphorylation in myeloid DC and macrophages. a). Myeloid DC and b). 
Macrophages were stimulated with LPS (10ng/ml) and CpG (500nM) in presence 
of varying doses of U0126. Lysates were immunoblotted for phosphorylated and 
total forms of ERK, p38 and JNK. U0126 titrations have been done 3 times with 
similar results. LPS and CpG were run on the same gel. Representative of 3 
eexperiments.   104 
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Figure 4.5: Lack of Tpl-2 abrogates TLR-induced ERK phosphorylation, but 
also impairs p38 phosphorylation. a) Macrophages and b) myeloid DC from Tpl-
2
-/- and littermate controls were stimulated with LPS or CpG and lysates were 
immunoblotted for MAP kinases. Blots have repeated done 3 individual times with 
similar results. LPS and CpG were run on separate gels. Exposure times are 
approximately the same for both LPS and CpG. Representative of 3 experiments. 
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Chapter 5 
Role of ERK phosphorylation in regulating cytokine 
production by TLR stimulated macrophages and DC  106 
5.0 Two approaches to determine the effect of ERK on cytokine production. 
 
  The main focus of this project was to study the regulation of cytokine production 
by the ERK MAP kinase pathway in macrophages and myeloid DC. We used the two 
approaches  described  in  chapter  4  to  determine  the  effect  of  ERK  activation  on 
production of TNF, IL-10, IL-12, and IFN-β.  
 
5.1 Effect of the MEK inhibitor U0126 or Tpl-2 on TNF induction 
 
5.1.1 Addition of MEK inhibitor U0126 inhibits TNF mRNA and protein production in 
macrophages and myeloid DC in response to LPS and CpG. 
 
It  has  previously  been  shown  that  blocking  ERK  phosphorylation 
pharmacologically with U0126 decreases TNF cytokine production in macrophages and 
human  monocytes  (Scherle  et  al.  1998;  Mancuso  et  al.  2002).  We  found  that  by 
inhibiting ERK activation in myeloid DC and macrophages upon stimulation with LPS 
or CpG using U0126, Tnf mRNA and protein were decreased (Figure 5.1.1). In both the 
myeloid DC and macrophages stimulated with LPS or CpG, the early Tnf mRNA was 
reduced  by  about  2-3  fold  after  treatment  with  U0126  (Figure  5.1.1a  and  5.1.1c). 
However, by 6 hours stimulation little difference was observed in Tnf mRNA upon LPS 
stimulation in the presence of U0126 versus controls. Upon stimulation with CpG in the 
presence of U0126, a 2-3 fold inhibition was observed.   107 
  The reduction in Tnf mRNA resulted in reduced TNF protein production (Figure 
5.1.1b and Figure 5.1.1d), in response to LPS or CpG, which was reduced in a dose-
dependent manner by U0126 treatment. Again TNF production upon U0126 addition 
was  only  partially  inhibited  by  about  3  fold  upon  stimulation  of  myeloid  DC  or 
macrophages upon stimulation with LPS or CpG.  
 
5.1.2  Induction  of  both  Tnf  mRNA  and  TNF  protein  is  reduced  in  Tpl-2  knockout 
macrophages or myeloid DC. 
 
  It  has  previously  been  reported  that  TNF  induction  in  the  Tpl-2  knockout 
macrophages is impaired due to post-transcriptional regulation (Dumitru et al. 2000). 
We further investigated the effects of Tpl-2 deletion on TNF production by stimulating 
macrophages from 5 individual Tpl-2 knockout mice and 5 individual littermate controls 
with LPS or CpG (Figure 5.1.2a). We lysed the cells at 0, 3, and 6 hours, extracted and 
purified the RNA and quantified the Tnf mRNA by real-time quantitative PCR. As seen 
in Figure 5.1.2a, the Tnf mRNA was reduced at 3 hours but returned to the same level as 
the littermate controls by 6 hours. The early reduction in Tnf mRNA is in contrast to the 
data by Dumitru et al. (2000), where the induction of Tnf mRNA levels by LPS were 
reported to be unaffected by the Tpl-2 deficiency (Dumitru et al. 2000).  
Supernatant was collected from the same cells used for the preparation of mRNA 
and an immunoassay was performed to determine the effects of deletion of Tpl-2 on 
TNF  protein  production  (Figure  5.1.2b).  Induction  of  TNF  protein  was  completely 
inhibited  in  the  Tpl-2  knockout  macrophages  in  response  to  LPS  or CpG.  Our data   108 
suggest that TNF may be regulated at both the transcriptional and post-transcriptional 
level by Tpl-2. 
 
5.1.3  TLR  induction  of  Tnf  mRNA  and  TNF  protein  is  impaired  in  Tpl-2  deficient 
myeloid DC. 
 
We  next  investigated  whether  TNF  production  was  regulated  by  Tpl-2  in 
myeloid DC. We stimulated purified myeloid DC generated from bone marrow from 
Tpl-2 knockout mice and littermate controls with LPS or CpG (Figure 5.1.3). Induction 
of Tnf mRNA was reduced in the Tpl-2 knockout DC stimulated with LPS or CpG as 
compared to littermate control cells (Figure 5.1.3a), similar to the effects seen in the 
macrophages. Likewise induction of TNF protein by LPS or CpG was reduced in Tpl-2 
deficient DC, however, production of TNF protein in the DC in response to LPS or CpG 
was not inhibited to the same degree as in the macrophages (Figure 5.1.3b). 
 
5.1.4 Splenic DC from the Tpl-2 knockout have reduced TNF production. 
 
  As both the myeloid DC and macrophage have been cultured in vitro for 7 days 
before being used in any stimulation assays, we wanted to verify that the Tpl-2 was also 
required  for  optimal  TNF  induction  by  ex  vivo  DC.  DC  were  purified  from  Tpl-2 
knockout and littermate control spleens by positive selection for CD11c
+ expression by 
flow  cytometry.  These  cells  were  then  stimulated  with  CpG  for  20  hours  and  the 
supernatants collected and TNF protein measured by immunoassay. We chose CpG as   109 
splenic  DC  have  been  shown  to  be  more  responsive  to  CpG  than  LPS  stimulation 
(Boonstra et al. 2003). In the splenic DC from Tpl-2 knockouts, TNF protein production 
was again reduced as compared to control DC, although not completely inhibited in the 
absence of Tpl-2 (Figure 5.1.4). The level of inhibition was very similar to in vitro 
generated myeloid DC from the Tpl-2 deficient mice (Figure 5.1.3b) and also similar to 
bone marrow derived myeloid DC treated with the U0126 inhibitor (Figure 5.1.1b). 
 
5.1.6 Discussion. 
 
The MEK inhibitor U0126 reduced but did not completely turn off induction of 
Tnf mRNA and TNF protein after stimulation with LPS or CpG in either macrophages or 
myeloid DC (Figure 5.1.1) indicating that ERK activation was not absolutely essential 
for TNF production. The effect of U0126 was much more pronounced on induction of 
the TNF protein than on Tnf mRNA. However, TNF protein induction in Tpl-2 deficient 
macrophages was completely inhibited upon TLR stimulation (Figure 5.1.2b), whereas 
the effects on Tnf mRNA were transient, a reduction was only observed at 3 hours of 
stimulation and lost by 6 hours in Tpl-2 deficient mice as compared to wildtype controls 
(Figure 5.1.2a). Both myeloid and splenic DC from Tpl-2 deficient mice produced low 
levels of TNF protein upon TLR stimulations as compared to the wildtype cells although 
effects were not as pronounced as in macrophages where TNF protein was completely 
abrogated  in  Tpl-2
-/-  mice  (Figure  5.1.3  and  5.1.4).  The  more  pronounced  effect  of 
U0126/Tpl-2 deficiency on TNF protein levels versus mRNA levels may be explained 
by previous studies by Dumitru et al. (2000), who showed that the Tpl-2/ERK pathway   110 
regulated  TNF  production  at  a  post-transcriptional  level  as  they  found  that  LPS 
stimulated macrophages from Tpl-2 deficient mice produced no TNF protein but Tnf 
mRNA was not affected as compared to the wildtype macrophages. In a previous report 
by Dumitru et al. (2000), it was found that Tnf mRNA was upregulated normally in Tpl-
2 deficient macrophages in response to LPS, which led them to conclude that Tpl-2 and 
its  downstream  phosphorylation  of  ERK  regulated  TNF  post-transcriptionally.  In 
contrast  to  this  study,  we  have  found  that  induction  of  Tnf  mRNA  and  protein  in 
response to LPS or CpG is impaired in Tpl-2 deficient macrophages and myeloid DC at 
early time points. However, in our study at 6 hours the Tnf mRNA was the same in both 
the Tpl-2
-/- and the littermate control mouse cells (Figure 5.1.2). In the study by Dumitru 
et al. (2000), the levels of Tnf mRNA may have been at too high a level to quantitate 
accurately,  since  the  cells  were  stimulated  with  a  very  high  concentration  of  LPS 
(1µg/ml) and analysed by Northern blot using only one time point. Furthermore our 
studies point out small effects at 3 hours after stimulation, which are lost by 6 hours. 
Therefore subtle changes in Tnf mRNA expression in the Tpl-2 deficient macrophages 
may have been missed in the Dumitru et al. (2000) study. Our data suggest that to a 
small extent, TNF induction was regulated by Tpl-2/ERK both at the level of mRNA 
induction but support a role for post-transcriptional regulation in both macrophages and 
myeloid DC by Tpl-2, since the effects of Tpl-2/ERK abrogation on the protein was 
more pronounced than those on the mRNA (Figure 5.1.2 and 5.1.3). Both these cell 
types  responded  in  a  similar  way  upon  stimulation  with  LPS  and  CpG,  where  we 
detected a decrease in Tnf mRNA in Tpl-2 deficient macrophages at 3 hours, which 
returned to normal after 6 hours. We also detected a decrease in TNF protein. We also   111 
verified the effects on TNF protein in purified splenic DC. Again we saw a reduction in 
TNF in the Tpl-2
-/- cells compared to the littermate controls (Figure 5.1.4). Thus the data 
obtained from ex vivo generated DC are very similar to the data obtained from in vitro 
generated DC and macrophages. 
We show here however that Tnf mRNA expression was clearly reduced when 
ERK activation was blocked by U0126 or Tpl-2 deficiency. These data indicate that the 
Tpl-2/ERK pathway regulates TNF production at two levels; mRNA induction and post-
transcriptionally although the effects on Tnf mRNA are small and transient. We found 
also however that the dramatic effects on TNF protein of blocking ERK signalling were 
in keeping with recent studies (Rousseau et al. 2008). It has been shown that production 
of TNF is dependent TACE, which cleaves pre-TNF into soluble TNF (Black et al. 
1997). Recently Rousseau et al. (2008) have reported that ERK activation was required 
to phosphorylate TACE in LPS stimulated macrophages for TNF protein production. 
This  could  in  part  explain  the  failure  to  induce  TNF  protein  in  Tpl-2  deficient 
macrophages as these do not activate ERK upon TLR stimulation. TACE has recently 
been  identified  as  a  substrate  of  ERK  (Rousseau  et  al.  2008),  required  for  TNF 
production. Our data are in keeping with showing that ERK activation is important for 
TNF protein production, to a greater extend than Tnf mRNA induction (Figure 5.1.2). 
We observed that whereas in Tpl-2 deficient cells show complete abrogation of TNF 
protein in response to LPS or CpG, ERK activation is completely abrogated and p38 
activation is decreased (Figure 4.5), whereas cells treated with U0126 show complete 
block in ERK activation without affecting p38 (Figure 4.3). The difference in the effects 
with  U0126  and  Tpl-2  deficiency  on  TNF  protein  induction  indicates  that  other   112 
pathways  than  ERK  may  play  a  role.  Indeed  we  show  in  Figure  4.5  that  p38 
phosphorylation is decreased in Tpl-2
-/- macrophages and DC. Tpl-2 has been reported to 
function as a MAP3 kinase directly upstream of MEK and ERK in macrophages and it 
has been reported that deletion of Tpl-2 does not affect activation of any other MAP 
kinase  pathways  (Dumitru  et  al.  2000;  Sugimoto  et  al.  2004).  However,  in 
overexpression  experiments,  Tpl-2  can  induce  activation  of  ERK,  JNK  and  p38 
(Patriotis et al. 1994; Salmeron et al. 1996). We have shown that at the doses used, 
U0126 does not affect the phosphorylation of p38, but we found that the lack of Tpl-2 
not  only  impaired  TLR-induced  ERK  phosphorylation  but  also  reduced  p38 
phosphorylation, albeit to a lesser extent in both macrophages and DC (Figure 4.5). In 
Tpl-2  deficient  macrophages,  the  reduction  of  p38  phosphorylation  was  more 
pronounced upon stimulation with CpG than with LPS. In Tpl-2 deficient myeloid DC, 
however, the reduction of p38 activation was similar with LPS or CpG stimulations. One 
of the reasons for the differences seen in p38 phosphorylation levels could be that LPS 
stimulation induces a much stronger p38 phosphorylation signal than is observed with 
CpG and thus effects may be more difficult to observe. The reasons for the differences 
in signal strength  are not known. One possibility is that CpG has to be internalised 
before it stimulates the cell in contrast to LPS, which stimulates directly at the plasma 
membrane.  Alternatively,  the  fact  that  LPS  utilises  both  the  MyD88/TIRAP  and  the 
TRIF/TRAM  pathways,  whereas  CpG  only  utilises  the  MyD88  pathway  may  be 
important  (Akira  and  Takeda  2004).  The  differences  observed  in  TNF  protein 
production between the macrophages and DC could be due to the fact that DC produce 
more TNF than macrophages or that DC use an additional pathway to also induce TNF.   113 
The  overall  conclusion  is  that  Tpl-2  is  a  MAP3  kinase  that  is  required  for  ERK 
phosphorylation,  but  also  plays  a  minor  role  in  p38  phosphorylation,  possibly  by 
functioning as a MAP3 kinase for MKK3/MKK6. This could explain why TNF was 
more affected in the Tpl-2 knockout than with the U0126 inhibitor. 
  In summary we show that ERK/Tpl-2 regulates transcription of TNF protein in 
keeping with Dumitru et al. (2000) but not posttranscriptionally. The U0126 inhibitor 
completely abrogates ERK activation but not TNF protein, whereas abrogation of Tpl-2 
lead to complete inhibition of TNF protein. We show that abrogation of Tpl-2 not only 
inhibits ERK phosphorylation but also affects p38 phosphorylation suggesting that there 
may  be  another  pathway  other  than  ERK,  which  plays  a  role  in  induction  of  TNF 
protein.        114 
5.2 Regulation of IL-12, IFN-β and IL-10 by Tpl-2 and ERK 
 
5.2.1 Background. 
 
  It has been shown that the MEK inhibitor U0126 can downregulate IL-10 protein 
production and  enhance the production of  IL-12p40 in macrophages stimulated with 
LPS or CpG (Hacker et al. 1999; Yi et al. 2002). Conflicting studies on the role of ERK 
activation in the regulation of IL-12 in myeloid DC have been published (Hacker et al. 
1999; Agrawal et al. 2003). Hacker et al. (1999) found that stimulation with LPS or 
CpG of murine myeloid DC in the presence of a MEK inhibitor did not lead to increased 
IL-12 production as compared to controls. On the other hand, Agrawal et al. (2003) 
reported  that  inhibition  of  ERK  activation  led  to  increased  IL-12p70  in  human  DC. 
Splenic DC from erk1 deficient mice also produced increased levels of IL-12p70 upon 
LPS stimulation as compared to wildtype mice (Dillon et al. 2004). Since these studies 
conflicted, it therefore remained unclear whether ERK played a role in regulating IL-12 
production in myeloid DC. 
It  is  known  that  IL-10  production  negatively  regulates  IL-12  production  by 
macrophages and DC in response to many stimuli (Moore et al. 2001). Whether the 
reported upregulation of IL-12 production caused by ERK inhibition in macrophages is a 
direct effect on the IL-12 gene or due to the reduced levels of induced IL-10 remains to 
be clarified. Yi et al. (2002) have shown that in splenocytes from IL-10 deficient mice 
pharmacological inhibition of ERK phosphorylation did not further enhance IL-12p40 
and IL-12p70 production suggesting that the increased IL-12 was due to decreased IL-10   115 
caused by the MEK inhibitor. However, the splenocytes consist of a mixture of cells, 
which may mask effects on individual populations, such as macrophages and DC. 
In another study, Hacker et al. (2006) suggested that IL-10 and type I IFN are co-
regulated. ERK has been shown to positively controls IL-10 production in macrophages. 
Thus we set out to determine the effects of the Tpl-2 pathway on macrophages and DC 
to  resolve  the  conflicting  reports  and  secondly  to  investigate  whether  ERK  activity 
similarly regulated IFN-β production. 
 
5.2.2 MEK inhibitor U0126 inhibits IL-10 but enhances IL-12p40, and IFN-β production 
in macrophages. 
 
Consistent with earlier studies by Yi et al. (2002), macrophages stimulated with 
LPS or CpG in the presence of U0126 showed decreased Il-10 mRNA induction and 
decreased IL-10 protein as compared to control cells (Figure 5.2.2). In contrast, Il-12p40 
mRNA induction and IL-12p40 protein levels were increased. Il-12p35 mRNA induction 
or IL-12p70 protein could not be detected in the macrophages in response to LPS or 
CpG, even in the presence of U0126. Interestingly, levels of Ifn-β mRNA and IFN-β 
protein were also increased in macrophages stimulated with LPS or CpG in the presence 
of U0126 relative to vehicle control treated cells.  
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5.2.3 IL-10 is decreased and IL-12p40, IL-12p70 and IFN-β are increased in myeloid 
DC treated with U0126 upon stimulation with LPS or CpG. 
 
To resolve conflicting results of ERK phosphorylation on the regulation of IL-12 
in DC in the literature, we wanted to clarify in our own studies a potential role for ERK 
activation in the regulation of IL-10 or IL-12 production in this cell type. 
  Figure 5.2.3 shows that Il-10 mRNA and IL-10 protein were decreased upon LPS 
or CpG stimulation in the presence of U0126. In contrast, Il-12p40 mRNA and IL-12p40 
protein levels were increased upon LPS or CpG stimulation in the presence of U0126. 
The increase in IL-12p40 protein upon U0126 treatment in DC stimulated with LPS was 
small, although a greater effect was observed at the mRNA level. Il-12p35 mRNA was 
increased whereas IL-12p70 protein was not detectable following LPS stimulation in the 
presence of U0126. Il-12p35 mRNA and IL-12p70 protein were both increased in the 
presence of U0126 after stimulation with CpG. Ifn-β mRNA and IFN-β protein were 
also  increased  upon  LPS  and  CpG  stimulation  in  the  presence  of  U0126.  U0126 
therefore had similar effects on IL-10, IL-12 and IFN-β production in macrophages and 
myeloid DC. 
 
5.2.4 The induction of IL-10 is decreased and IL-12 and IFN-β is increased in Tpl-2 
deficient macrophages. 
 
To date there has been only been one report on the effect of Tpl-2 deficiency in 
macrophages on IL-10 and IL-12p40 production (Sugimoto et al. 2004). It was found   117 
that IL-10 protein induction was increased in response to LPS and CpG in the Tpl-2 
deficient macrophages as compared to littermate controls. This result is surprising since 
our data show that blockade of ERK activation with U0126 decreases IL-10 induction 
after LPS and CpG stimulation of macrophages. Sugimoto et al. (2004) also found that 
IL-12p40  production  was  increased  in  Tpl-2  deficient  macrophages  upon  CpG 
stimulation but not altered upon LPS stimulation in the Tpl-2 deficient macrophages 
relative to wildtype cells (Sugimoto et al. 2004). Sugimoto et al. (2004) also showed that 
CpG induced ERK phosphorylation was found to be unaffected in the Tpl-2 deficient 
macrophages,  in  contrast  to  LPS  stimulation  where  ERK  phosphorylation  was 
completely abrogated. This is in sharp contrast to our studies where ERK activation was 
blocked in Tpl-2 deficient macrophages after LPS or CpG stimulation. Furthermore, our 
U0126 data show that blockade of ERK activation increases IL-12 production after both 
LPS and CpG stimulation. In this section we investigated further the role of Tpl-2 in 
regulating IL-10 and IL-12 production by macrophages stimulated with LPS or CpG. 
We stimulated Tpl-2 deficient and littermate control macrophages with LPS and CpG 
and examined cytokine mRNA induction by real-time quantitative PCR (Figure 5.2.4a 
and c) and cytokine production by immunoassay (Figure 5.2.4b and d). We found that 
IL-10  was  always  decreased  at  both  the  mRNA  and  protein  level  in  Tpl-2  deficient 
macrophages  stimulated  with  LPS  or  CpG  compared  to  littermate  control  cells.  In 
contrast, Il-12p40 and Il-12p35 mRNA as well as IL-12p40 and IL-12p70 protein were 
increased in the Tpl-2 deficient macrophages in response to LPS and CpG stimulation as 
compared to the littermate control macrophages. Ifn-β mRNA and IFN-β protein levels 
were  also  elevated  in  the  Tpl-2  deficient  macrophages  compared  to  the  littermate   118 
controls after stimulation with LPS or CpG. These data are consistent with but more 
pronounced than our findings with the U0126 inhibitor. 
 
5.2.5 IL-10 is decreased and IL-12 and IFN-β is increased in Tpl-2 deficient myeloid 
DC. 
 
  Sugimoto et al. (2004) have reported that IL-12p40 was increased but that IL-10 
production  was  also  increased  in  response  to  LPS  and  CpG  in  Tpl-2  deficient 
macrophages  as  compared  to  littermate  control  macrophages.  However,  in  Tpl-2 
deficient myeloid DC they only reported an increase in IL-12p40 but did not mention 
IL-10.  
  To investigate the effects on Tpl-2 on the production of IL-10, IL-12 and IFN-β, 
we stimulated in vitro generated bone marrow-derived myeloid DC, which were purified 
by flow cytometry on the basis of CD11c
+ from Tpl-2 deficient mice and littermate 
controls  with  LPS  and  CpG  and  examined  cytokine  mRNA  induction  by  real-time 
quantitative PCR (Figure 5.2.5a and c) and cytokine protein production by immunoassay 
(Figure 5.2.5b and d). The effects of Tpl-2 deficiency in the myeloid DC were similar to 
those found in the macrophages. Il-10 mRNA and IL-10 protein levels were significanty 
decreased, whereas Il-12p40 mRNA and IL-12p40 protein levels and Il-12p35 mRNA 
and  IL-12p70  protein  levels  were  increased  upon  LPS  or  CpG  stimulation  of  Tpl-2 
deficient myeloid DC as compared to the littermate controls. Furthermore, Ifn-β mRNA 
and  IFN-β  protein  levels  were  also  increased  in  the  Tpl-2  deficient  myeloid  DC   119 
compared to the littermate control cells. Effects on IL-12 protein were more pronounced 
than on mRNA expression. 
 
5.2.6 Splenic DC from Tpl-2 deficient mice produced increased levels of IL-12 and IFN-
β upon stimulation with CpG. 
 
  As all the data so far were obtained using macrophages or myeloid DC, which 
have been cultured in vitro for 7 days before stimulation, we wanted to confirm their 
physiological relevance using ex vivo cells that had not been cultured. To do this, we 
purified splenic DC by flow cytometry from Tpl-2 deficient mice and littermate controls 
and  stimulated  them  with  CpG  (TLR9)  for  20  hours  after  which  supernatants  were 
harvested (Figure 5.2.6). Splenic DC only express low levels of TLR4 and therefore 
respond poorly to LPS stimulation (Boonstra et al. 2003). In Tpl-2 deficient cells, IL-
12p40, IL-12p70, and IFN-β protein were increased upon stimulation as compared to 
splenic DC from littermate controls. However, there was no detectable IL-10 in either 
the littermate control or knockout splenic DC. The upregulation of IL-12 and IFN-β in 
the absence of Tpl-2 were similar to the findings we had with bone marrow derived 
macrophages and myeloid DC generated in vitro from the Tpl-2 deficient mice. 
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5.2.7  IL-12  production  is  regulated  through  an  ERK  dependent  and  independent 
pathway via IL-10. 
 
  We have shown that in both macrophages and myeloid DC from Tpl-2 deficient 
mice or in wildtype macrophages and myeloid DC treated with U0126, the inflammatory 
cytokines IL-12p40 and IFN-β were increased, whereas the regulatory cytokine IL-10 
was decreased upon LPS or CpG stimulation. In wildtype macrophages stimulated with 
LPS or CpG in the presence or absence of U0126, IL-12p70 could not be detected but in 
wildtype DC stimulated with CpG, IL-12p70 induction could be observed. However, 
Tpl-2 deficient macrophages produced IL-12p70 in response to LPS and CpG. Thus Tpl-
2 negatively regulated the induction of IL-12p70. The observed increased levels of IL-12 
and IFN-β following blockade of the Tpl-2/ERK pathway could result indirectly from 
the reduced levels of IL-10. Alternatively, the Tpl-2/ERK pathway may directly regulate 
the induction of IL-12 and IFN-β. 
We investigated whether the increase in IL-12p40 and IL-12p70 we detected in 
the Tpl-2 deficient cells and in the littermate control cells treated with U0126 was a 
direct negative effect of the ERK signalling pathway on IL-12 induction or rather the 
indirect consequence of IL-10 downregulation. To address this question, macrophages 
from IL-10 deficient mice and littermate controls were stimulated with LPS and CpG in 
the presence or absence of U0126 (Figure 5.2.7). In the absence of U0126, we observed 
that both IL-12p40 and IL-12p70 were increased in the IL-10 deficient macrophages as 
compared  to  littermate  control  cells  as  previously  documented  (Moore  et  al.  2001).   121 
However, upon addition of U0126 to the IL-10 deficient macrophages stimulated with 
LPS or CpG, IL-12p40 and IL-12p70 production were further enhanced. 
We conclude that the Tpl-2/ERK pathway does downregulate IL-12 in part by 
inducing the production of IL-10. However, the dramatic increase in IL-12 levels in LPS 
or CpG stimulated IL-10 deficient macrophages after U0126 treatment, indicates that IL-
12 induction was also negatively regulated directly by ERK activation independently of 
IL-10. This has not previously  been  reported  and is in contrast to data by  Yi et al. 
(2002), who showed no effect on IL-12 in IL-10 deficient whole spleen cells treated with 
U0126. 
 
5.2.8 IL-12 is regulated by both ERK and IL-10 as shown by the Tpl-2/IL-10 double 
knockout. 
 
  To  corroborate  these  pharmacological  data,  we  generated  mice  that  were 
deficient in both Tpl-2 and IL-10. We stimulated macrophages from these mice with 
LPS and CpG and compared them to IL-10 deficient littermate control cells (Figure 
5.2.8). We found that in the absence of both Tpl-2 and IL-10, IL-12p40 and IL-12p70 
were  dramatically  increased  as  compared  to  the  IL-10  deficient  cells.  The  data  are 
consistent with the effects of the U0126 inhibitor (Figure 5.2.7). We therefore conclude 
that IL-12 production is negatively regulated directly via ERK signalling independently 
of IL-10 in addition to the effect mediated via IL-10. 
  We also found that TNF protein levels were reduced in the Tpl-2/IL-10 deficient 
macrophages as compared to the IL-10 deficient macrophages upon stimulation with   122 
LPS or CpG. This suggests that TNF is upregulated through ERK but also that ERK-
induced IL-10 has a negative effect on TNF production. 
 
5.2.9 Discussion. 
 
We have used two approaches to examine the role of ERK activation on the 
production of IL-10, IL-12 and IFN-β by macrophages and DC stimulated with LPS and 
CpG. First, we used the MEK inhibitor U0126 to block ERK phosphorylation. U0126 
completely  inhibited  phosphorylation  and  activation  of  ERK,  whilst  not  affecting 
phosphorylation of p38 and JNK at the doses used in this study (Figure 4.1). Second, we 
used cells from Tpl-2 deficient mice. LPS and CpG induction of ERK phosphorylation 
was abrogated in Tpl-2 deficient macrophages, consistent with published data (Dumitru 
et  al.  2000).  However,  we  have  now  found  that  phosphorylation  of  p38  was  also 
reduced, albeit to a lesser extent, in both Tpl-2 deficient macrophages and myeloid DC 
upon stimulation with LPS or CpG (Figure 4.3). Thus, the effects of Tpl-2 deficiency on 
cytokine production may result from impaired activation of both ERK and p38 after 
TLR stimulation. 
  We have shown macrophages stimulated with LPS or CpG in the presence of 
U0126 displayed decreased induction of IL-10 mRNA and protein (Figure 5.2.1). These 
data are consistent with Yi et al. (2002), who showed that the RAW 264.1 macrophage 
cell line had decreased IL-10 production in the presence of U0126 upon stimulation with 
LPS or CpG. We also found that Tpl-2 deficient macrophages had decreased IL-10 upon 
stimulation with LPS and CpG as compared to littermate control cells (Figure 4.2.3).   123 
This finding is in contrast data from Sugimoto et al. (2004), who showed increased 
levels of IL-10 protein upon macrophage stimulation with CpG resulting from Tpl-2 
deficiency. One possible explanation for the differences observed between our data and 
those of Sugimoto et al. (2004), could be that the Tpl-2 deficient mice we used were 
generated in different labs, although both mice show complete lack of the Tpl-2 kinase. 
Another  explanation  could  be  that  the  CpG  used  in  the  Sugimoto  study  was 
contaminated with a non-TLR ligand that activates ERK independently of Tpl-2. We test 
all our CpG stock on TLR4, TLR9 and MyD88 deficient mice and have ensured that 
there is no contamination present.  
In another study supporting our findings, it was found that activation of ERK 
was abrogated in NF-κB1 deficient macrophages, which have markedly reduced Tpl-2 
protein, and this led to reduced levels of IL-10 protein upon stimulation with both LPS 
and CpG. Reconstitution with RAF:ER restored ERK phosphorylation in the NF-κB1 
deficient macrophages and induction of IL-10 protein (Banerjee et al. 2006). Together 
with our data, these results strongly indicate that ERK activition positively regulates IL-
10 production. 
  We have shown that both IL-10 mRNA and protein levels are reduced in myeloid 
DC stimulated with LPS and CpG in the presence of U0126 (Figure 5.2.2). This is in 
agreement with Agrawal et al. (2003), who showed that human DC stimulated with LPS 
in the presence of the MEK inhibitor U0126 had decreased levels of IL-10 protein. In 
addition, we confirmed this positive role for ERK activation by demonstrating that LPS 
and  CpG  induction  of  IL-10  is  also  reduced  in  Tpl-2  deficient  myeloid  DC  (Figure 
5.2.4).   124 
  We have shown that macrophages stimulated with LPS or CpG in the presence of 
U0126 have increased IL-12p40 at both the mRNA and protein levels (Figure 5.2.1). 
This is consistent with data from Yi et al. (2002), who found that both IL-12p40 and IL-
12p70 protein levels are increased in RAW macrophages in the presence of U0126 upon 
stimulation with either LPS or CpG. We extended these findings using Tpl-2 deficient 
mice, where we found that Il-12p40 mRNA and IL-12p40 protein, as well as Il-12p35 
mRNA and IL-12p70 protein levels were increased upon stimulation with LPS or CpG 
in Tpl-2 deficient macrophages as compared to wildtype controls (Figure 5.2.3). This 
finding  agrees  with  data  from  Sugimoto  et  al.  (2004),  who  found  IL-12p40  protein 
production is increased in macrophages stimulated with LPS or CpG in the absence of 
Tpl-2. We could not detect any IL-12p70 protein in the presence of U0126 in wildtype 
macrophages,  which  could  be  due  to  the  sensitivity  of  our  assay.  In Tpl-2  deficient 
macrophages we consistently detected an increase in IL-12p70 levels upon LPS or CpG 
stimulation.  The  difference  in  the  effect  of  Tpl-2  deficiency  compared  to  U0126 
treatment with respect to IL-12p70 induction may suggest a function for Tpl-2 additional 
to the effect on ERK regulation. One possibility could be via p38 activation since we 
show a decrease in p38 phosphorylation in Tpl-2 deficient macrophages and DC (Figure 
4.3), although p38 has been suggested to be required for IL-12 induction (Tanaka et al. 
2002). Thus it is possible that another downstream signal of Tpl-2 independent ERK 
activation negatively regulates IL-12. 
  In myeloid DC stimulated with LPS or CpG, we found IL-12p40 and IL-12p70 
production was increased at both the mRNA and the protein level by U0126 treatment 
(Figure  5.2.2).  Consistent  with  our  data,  Agrawal  et  al.  (2003),  found  that  human   125 
monocyte derived DC stimulated with LPS in the presence of U0126 produced increased 
IL-12p70 protein. However, Hacker et al. (1999) found that myeloid DC stimulated with 
CpG in the presence of a MEK inhibitor did not lead to increased levels of IL-12 in 
keeping with the lack of observed ERK phosphorylation in the cells used in their study. 
However, as discussed earlier Hacker et al. (1999) did show that IL-12 is increased in 
macrophages  following  MEK  inhibition.  A  possible  explanation  for  the  discrepancy 
between our data to those of Hacker et al. (1999) could be that the stimulation time 
points used in the Hacker et al. (1999) study are only 3 and 7 hours for IL-12 protein 
induction whereas we have shown that IL-12 protein was induced only after 20 hours 
stimulation with CpG (Figure 3.3). Also the lack of ERK phosphorylation reported by 
Hacker et al. (1999) in DC in response to TLR ligation maybe due to lack of sensitivity 
in their assays compounded by high background levels of ERK phosphorylation in DC 
in the absence of stimuli. 
  We confirmed the inhibitory effect of ERK activation reported by Agrawal et al. 
(2003) on the induction of IL-12p40 and IL-12p70 in myeloid DC stimulated with LPS 
or CpG from Tpl-2 deficient mice (Figure 5.2.4). These data are in keeping with the 
results  by  Sugimoto  et  al.  (2004),  who  showed  that  Tpl-2  deficient  myeloid  DC 
stimulated with LPS or CpG had increased IL-12p40 levels as compared to littermate 
control DC. 
  Using  macrophages  from  IL-10  deficient  mice,  we  have  shown  that  in  the 
absence of IL-10, IL-12 levels are enhanced following LPS or CpG stimulation (Figure 
5.2.8  and  5.2.7).  Additionally,  pharmacological  blockade  of  ERK  phosphorylation 
increased IL-12 levels in the IL-10 deficient cells. Therefore the negative effects of ERK   126 
activation on IL-12 production are mediated both indirectly via IL-10 production and 
directly via effects on IL-12 transcription by as yet unknown downstream molecules. 
This is in contrast to data obtained by Yi et al. (2002), who showed that splenocytes 
from IL-10 deficient mice stimulated with CpG in the presence of U0126 did not show 
enhanced IL-12p40 and IL-12p70 protein levels. An explanation for this discrepancy 
could be that we used macrophages, whereas Yi et al. (2002) used whole spleen cell 
suspensions, which have a mixed cell population and therefore masked the effects on 
macrophages and DC. Furthermore of note was that Yi et al. (2002) detected IL-10 in 
splenocytes from Il-10
-/-  indicating that the mice could have been mistyped. 
  A  possible  mechanism  of  ERK  regulation  of  IL-12  transcription  has  been 
suggested to be dependent on c-Fos induction (Agrawal et al. 2003; Dillon et al. 2004). 
Agrawal et al. (2003) show that stimulation of human monocyte-derived DC stimulated 
with LPS (TLR4), flagellin (TLR5), Pam3cys (TLR2) or schistosome egg antigen (SEA) 
(Th2 stimulus) induced enhanced levels of c-Fos, however, Pam3cys and SEA induced 
greater  levels  of  c-Fos  when  compared  to  DC  stimulated  with  LPS  or  flagellin. 
Inhibition of c-Fos expression by si-RNA showed that all the stimuli used produced 
enhanced levels of IL-12p70. In the absence of c-Fos, even a Th2 stimuli such as SEA 
produced high levels of IL-12p70 and thus skewing the response towards a Th1 profile. 
Agrawal  et  al.  (2003)  concludes  that  c-Fos  is  important  in  regulating  IL-12p70 
production. Dillon et al. (2004), showed that wildtype murine splenic DC stimulated 
LPS or Pam3cys produce low levels of IL-12p70 and high level of IL-10, whereas c-fos
-
/- DC produce enhanced levels of  IL-12p70 and reduced levels of  IL-10. This again 
indicates  that  c-Fos  is  important  in  the  regulation  of  IL-12,  but  c-Fos.  It  is  as  yet   127 
unknown whether c-Fos has a direct effect to regulate IL-12 production or does so by 
induction of IL-10. 
  It has been shown that sustained ERK activation results in phosphorylation and 
stabilisation of c-Fos (Murphy et al. 2002). The tpl-2
-/- mouse cannot activate ERK and 
upon stimulation with LPS or CpG induces enhanced levels of IL-12 and reduced levels 
of  IL-10  as  compared  to  the  wildtype.  Figure  5.2.9  shows  a  proposed  potential 
mechanism of regulation of IL-10, IL-12 and IFN-β by ERK. By summarising the data 
from Agrawal et al. (2003), Dillon et at. (2004), Banerjee et al. (2006) and our own 
results, three possible pathways of IL-12 and IFN-β regulation by ERK can be identified 
(Figure 5.2.9). 1). ERK activation negatively regulates IL-12 and IFN-β directly through 
c-Fos.  2).  ERK  activation  negatively  regulates  IL-12  and  IFN-β  indirectly  through 
transcription factor c-Fos via IL-10. 3). ERK activation indirectly regulate IL-12 and 
IFN-β  through  another  transcription  factor  via  IL-10.  4).  ERK  activation  negatively 
regulates IL-12 and IFN-β directly through another transcription factor. 
  Finally, we have shown that IFN-β is upregulated at both the mRNA and the 
protein  levels  in  macrophages  and  myeloid  DC  stimulated  with  LPS  or  CpG  in  the 
presence of MEK inhibitor U0126 or in the absence of Tpl-2 (Figures 5.2.1, 5.2.2, 5.2.3 
and 5.2.4). We do not know whether this upregulation of IFN-β production is caused by 
the reduced levels of IL-10 seen in the absence of ERK activation. Recently, it was 
suggested that IL-10 and type I IFN are co-ordinately regulated (Hacker et al. 2006). 
This  group  showed  that macrophages  from  TRAF3  deficient  mice  showed  defective 
upregulation of both IL-10 and type I IFN production, whereas levels of IL-12 and IL-6 
were increased in TRAF3 deficient bone marrow derived macrophages stimulated with   128 
TLR  ligands.  TRAF3  is  an  important  adaptor  protein  in  TLR  signalling,  which  is 
recruited to MyD88 (Hacker et al. 2006). From these data the group concluded that IL-
10  and  type  I  IFN  are  co-ordinately  regulated  and  that  the  other  proinflammatory 
cytokines  were  enhanced  due  to  reduced  levels  of  IL-10  in  the  TRAF3  deficient 
macrophages. However, in another study it was shown that IL-10 production induced by 
LPS was reduced in macrophages lacking either MyD88 or TRIF (Boonstra et al. 2006), 
however, IFN-β induction by LPS was unaffected in MyD88 deficient macrophages but 
reduced in TRIF deficient macrophages (Boonstra et al. 2006). This already suggested 
that  IFN-β  and  IL-10  may  be  independently  regulated  since  IFN-β  production  in 
macrophages stimulated with LPS is dependent on TRIF and not MyD88, whereas IL-10 
is dependent on both. Consistent with the independent regulation of IL-10 and IFN-β, 
our  data  indicate  that  the  Tpl-2/MEK/ERK  pathway  positively  regulates  IL-10 
production but negatively controls type I IFN production since IFN-β is increased by the 
addition  of  U0126  to  wildtype  cells  or  in  Tpl-2  deficient  macrophages  and  DC  as 
compared to littermate control cells. However, it is unclear whether the elevated IFN-β 
levels  are  the  consequence  of  reduced  levels  of  IL-10  or  a  direct  effect  of  ERK 
activation on IFN-β induction. Regardless, although upstream adaptors and signalling 
molecules  such  as  MyD88,  TRIF  and  TRAF3  may  co-ordinately  regulate  IL-10  and 
IFN-β  there  appears  to  be  independent  downstream  signal  in  response  to  ERK 
phosphorylation, which may lead to differential regulation of IL-10 and IL-12 and IFN-β 
in macrophages and DC. 
  In conclusion, we have shown that in the absence of Tpl-2/ERK activation, IL-10 
production  is  decreased  and  IL-12  and  IFN-β  production  are  increased  in  both   129 
macrophages and myeloid DC. Our data show for the first time that IL-12 and IFN-β are 
negatively regulated by IL-10 as previously reported but we also show that the IL-12 
and IFN-β are negatively regulated by Tpl-2/ERK activation in the complete absence of 
IL-10 in myeloid DC and macrophages.   130 
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Figure 5.1.1: U0126 inhibits LPS and CpG induction of TNF mRNA and 
protein in macrophages and myeloid DC. a and b) Myeloid DC and 
macrophages were stimulated with LPS or CpG and mRNA levels determined 
real-time quantitative PCR. c and d) Supernatants were collected at 6 hours for 
quantitation of TNF protein by immunoassay.   132 
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Figure 5.1.2:TLR induction of both TNF mRNA and protein is reduced in the 
Tpl-2
-/- macrophages. Macrophages from Tpl-2
-/- (open squares) and littermate 
controls (closed squares) were stimulated with LPS or CpG for the given times. a) 
Cells were lysed for RNA and real-time quantitative PCR preformed. b) 
Supernatants were collected for immunoassay.   133 
a) mRNA 
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Figure 5.1.3: TNF production is reduced in Tpl-2 deficient myeloid DC. Sorted 
purified GM-DC were stimulated with LPS or CpG from Tpl-2
-/- (closed bars) or 
littermate controls (open bars). a) Cells were lysed for RNA after 3 hours and Tnf 
mRNA was quantified by Real-time quantitative PCR. b) Supernatants were 
collected after 6 hours stimulation for immunoassay. Each bar represents 
triplicates. This has been repeated 3 times with similar results. 
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Figure 5.1.4: CpG induced TNF production is reduced in Tpl-2 deficient 
splenic DC. Splenic DC were purified and stimulated with CpG for 20 hours 
before supernatant was collected for TNF immunoassay. Each bar represents 
triplicates. Similar results have been obtained on 3 separate occasions.   135 
Figure 5.2.2: U0126 treatment decreases IL-10 but increases IL-12p40 and 
IFN-β in macrophages.  a, b) Macrophages stimulated with LPS or, c, d) CpG. 
mRNA induction (a, c) was analysed after 6 hours stimulation by real-time 
quantitative PCR and supernatants (b, d) were harvested after 20 hours and to 
measure cytokine protein by immunoassay. 
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Figure 5.2.3: U0126 treatment decreases IL-10 but increases IL-12 and IFN-β 
in myeloid DC stimulated with LPS or CpG.  a and b) myeloid DC stimulated 
with LPS or, c and d) CpG. mRNA (a and c) was harvested after 6 hours and 
quantified by real-time PCR and supernatants (b and d) were harvested after 20 
hours and protein levels were quantified by immunoassay. Experiment has been 
repeated 3 times with similar results.   137 
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Figure 5.2.4: Lack of Tpl-2 leads to decreased IL-10 but increased IL-12 and 
IFN-β production in macrophages stimulated with LPS and CpG.  a and b) 
Macrophages from Tpl-2
-/- and littermate controls were stimulated with LPS or, c 
and d) CpG. mRNA (a and c) was harvested after 6 hours and cytokine induction 
was checked by real-time quantitative PCR and supernatants (b and d) were 
harvested after 20 hours and cytokine protein levels were measured by 
immunoassay. 
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Figure 5.2.5: Lack of Tpl-2 impaired IL-10 induction but increased IL-12 and 
IFN-β production in myeloid DC stimulated with LPS or CpG.  a and b) 
Myeloid DC from Tpl-2 knockouts and littermate controls were stimulated with 
LPS or, c and d) CpG. mRNA (a and c) was harvested after 6 hours and cytokine 
induction was checked by real-time quantitative PCR and supernatants (b and d) 
were harvested after 20 hours and cytokine protein levels were measured by 
immunoassay. 
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Figure 5.2.6: Lack of Tpl-2 increases IL-12 and IFN-β production in splenic 
DC. Purified splenic DC from Tpl-2 knockouts and littermate controls were 
stimulated with CpG for 20 hours and protein levels tested by immunoassay   140 
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Chapter 6 
Tpl-2/IL-10 double knockout phenotype   144 
6.1 Tpl-2
-/- x Il-10
-/- mice show weight loss.  
 
We  generated  Tpl-2
-/-  x  Il-10
-/-  (Tpl-2/IL-10  knockout)  mice  to  investigate  a 
potential mechanism for Tpl-2 in down regulation of IL-12 and IFN-β in the complete 
absence  of  IL-10.  It  became  clear  that  by  8  weeks  of  age  the  double  knockouts 
developed diarrhoea, suggesting the development of colitis. It is well established that IL-
10 deficient mice can develop colitis, when kept in a non-pathogen free environment 
(Kuhn et al. 1993; Davidson et al. 1996). However, when on a C57BL/6 background 
these mice are usually between 4-6 months old before they develop diarrhoea (Davidson 
et al. 1996) and our results. Tpl-2 deficient mice however never develop colitis. Since 
our  findings  demonstrate  that  the  Tpl-2
-/-  x  Il-10
-/-  mice  show  early  onset  of  colitis 
compared to the Il-10
-/- mice, implying that the absence of Tpl-2 accelerates disease 
onset caused by IL-10 deficiency. 
  We  generated  mice  from  4  genotypes  (wildtype,  Tpl-2  knockout,  IL-10 
knockout, and Tpl-2/IL-10 knockout) and the females were mixed in the cages to ensure 
that  they  experienced  the  same  environment  (Garrett  et  al.  2007).  Mice  were  then 
weighed weekly from 4 weeks of age until 33 weeks of age as a general indicator of 
health of the mice (Figure 6.1). It became clear that already at 7 weeks, the Tpl-2
-/- x Il-
10
-/- mice were smaller than the single knockouts and the littermate controls, a trend that 
continued over time. At 13 weeks, the IL-10 deficient mice were also smaller that the 
wildtype or Tpl-2 deficient mice, but not as small as the Tpl-2
-/- x Il-10
-/- mice. 
  To begin with there was no noticeable weight loss in the Tpl-2
-/- x Il-10
-/- mice, 
but only failure to put on weight compared to the other genotypes in the cage. However,   145 
as the mice got older, weight loss was noted, and was sometimes so severe that the 
mouse had to be culled. This only ever occurred in the Tpl-2
-/- x Il-10
-/- mice within the 
timeframe of these experiments. The failure to put on weight coincided with the onset of 
diarrhoea. We never recorded any significant weight loss, but only slower growth as 
compared to the littermate controls in the IL-10 knockout over the 33 weeks they were 
monitored.  
 
6.2  Colons  from  the  Tpl-2
-/-  x  Il-10
-/-  mice  are  shorter  but  heavier  than  those  from 
littermates. 
 
  As the Tpl-2
-/- x Il-10
-/- mice either became too ill, and thus had to be sacrificed 
according to our project license, or as in the case of the single knockout or wildtype 
reached 33 weeks of age, the intestines were removed and fixed in formalin for further 
investigation.  We  noticed  a  difference  in  gut  size  between  the  different  genotypes. 
Figure 6.2.1 shows a representative photo of the colons from wildtype, Tpl-2 knockout, 
IL-10 knockout, and the Tpl-2
-/- x Il-10
-/- mice. It is very clear that the Tpl-2
-/- x Il-10
-/- 
mice have a shorter but thicker colon compared to the wildtype and Tpl-2 deficient mice. 
The IL-10 deficient mouse colon was slightly thicker and shorter, but not to the same 
extent as the Tpl-2
-/- x Il-10
-/- mice coincident with the accelerated weight loss in the Tpl-
2
-/- x Il-10
-/- mice. 
  We also recorded the length and weight of the colons when we took them out to 
quantify these differences. Figure 6.2.2 shows the length and weight of guts measured 
from the colon to the caecum from Tpl-2 knockout, IL-10 knockout and Tpl-2
-/- x Il-10
-/-   146 
mice  aged  33  weeks.  The  average  length  and  weight  for  both  the  Tpl-2  and  IL-10 
knockouts were around 97mm and 1.2g, whereas for the Tpl-2
-/- x Il-10
-/- mice
 knockouts 
the length and weight was 75mm and 1.6g respectively. However, in order to verify the 
phenotype, larger numbers are required, particularly since is not an absolute phenotype 
as the Il-10
-/- mice also develop colitis, but rather an accelerated phenotype.  
 
6.3 Intestinal pathology. 
 
  We  carried  out  histological  analysis  on  different  sections  of  the  colon  and 
caecum to investigate whether the differences in the length and weight of the colon from 
the Tpl-2
-/- x Il-10
-/- mice were due to colitis. Figure 6.3 shows all 4 genotypes at 20 
weeks of age. The morphology of the wildtype and the Tpl-2 knockout colons looked 
similar  with  no  infiltrates.  Colons  from  the  IL-10  knockout  mice  did  not  look  very 
different to the wildtype, but there was a slight level of infiltrate in the tissue. However, 
the Tpl-2
-/- x Il-10
-/- mice showed extensive infiltration of inflammatory cells and the gut 
structure was completely disrupted, indicating severe colitis. 
  Taking all the preliminary data together, our results indicate that the Tpl-2
-/- x Il-
10
-/- mice develop colitis at an earlier stage than the IL-10 deficient mice. On the other 
hand there is no evidence that the Tpl-2 deficient mice ever develop colitis.  
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6.4 Discussion. 
 
We generated Tpl-2
-/- x Il-10
-/- mice by crossing the Tpl-2
-/- mouse to the  Il-10
-/- 
mouse. We did this in order to investigate the potential regulation of IL-12 and IFN-β by 
Tpl-2  in  the  complete  absence  of  IL-10.  Whilst  waiting  to  get  enough  mice  for  an 
experiment, we observed that by 6-8 weeks of age, the Tpl-2
-/- x Il-10
-/- mice developed 
diarrhoea, whereas the other genotypes (wildtype, Tpl-2
-/- or Il-10
-/- mice) at that stage 
displayed no sign of illness. We show that this phenotype resulted in accelerated weight 
loss in the Tpl-2
-/- x Il-10
-/- mice. Colons of these mice showed a severe inflammatory 
infiltrate, which was absent in the control, Tpl-2
-/-and Il-10
-/- mice at that age housed in 
the same cages. This has recently been shown to be important, since T-bet
-/- x RAG2
-/- 
mice develop spontaneous colitis, which can be transferred to littermate controls when 
they are housed in the same cage (Garrett et al. 2007).  
 
6.5 Potential mechanism. 
 
6.5.1 The role of cytokines in development of colitis. 
 
Colitis has been reported to develop in IL-10 deficient mice (Kuhn et al. 1993), 
although it is dependent on colonisation of the gut flora, it can also be induced by the 
transfer of CD25
- or CD45RB
high CD4
+ T cells into RAG deficient mice (Izcue et al. 
2006). Colitis has been shown to be dependent on TNF, IFN-γ, IL-12 and IL-23 (Kuhn 
et  al.  1993;  Hue  et  al.  2006;  Kullberg  et  al.  2006).  The  ability  of  anti-IL-12p40 
antibodies  (which  recognise  both  IL-12  and  IL-23)  and  IL-12p40  deficient  mice  to   148 
protect  from  colitis  was  more  recently  shown  to  be  attributed  to  blocking  of  IL-23 
(Kullberg et al. 2001; Kullberg et al. 2006). These different systems have been used as 
models of ulcerative colitis in humans. In keeping with findings in mouse models, anti-
TNF antibodies have also been shown to reduce symptoms of Crohn’s disease (Hanauer 
et al. 2006). 
IL-10 is important in suppressing the production of proinflammatory cytokines 
TNF and IFN-γ and also Th1 cell differentiation (Fiorentino et al. 1991; Fiorentino et al. 
1991; Rennick et al. 1995). IL-12 also has a role in the development of colitis (Leach et 
al. 1996; Asseman et al. 1999). IL-12 was originally thought to be responsible for the 
gut pathology seen in the IL-10 knockout mouse (Kuhn et al. 1993).  
 
6.5.2 The role of TNF in colitis. 
   
  As discussed above TNF have been shown to an important mediator of colitis. 
Kontoyiannis et al. (1999) show that Tnf
∆ARE deficient mice, which have a defect in 
posttranslational regulation of Tnf mRNA, develop colitis. This group showed that this 
overproduction  of  TNF  in  the  intestine  can  lead  to  overproduction  of  other 
proinflammatory cytokines such as IL-12 and IFN-γ, which they suggested may cause 
the  tissue  damage  observed  in  colitis  although  they  did  not  look  at  IL-23  or  IL-17 
(Kontoyiannis et al. 2002). 
Based on our in vitro studies with macrophages from the Tpl-2
-/- x Il-10
-/- mice 
(Figure 5.2.9) we show that these mice produce lower levels of TNF as compared to the   149 
Il-10
-/- mice. We therefore did not expect that the Tpl-2
-/- x Il-10
-/- mice would develop 
accelerated colitis.  
   
6.5.3 The role of IL-12 in colitis. 
 
We show earlier that the Tpl-2
-/- x Il-10
-/- deficient in vitro macrophages have 
higher IL-12p40 and IL-12p70 levels compared to the Il-10
-/- mouse (Figure 5.2.9). As 
yet however, we have not determined the serum or gut levels of these cytokines in the 
Tpl-2
-/- x Il-10
-/- mice as compared to the Tpl-2
-/- or the Il-10
-/- mice. The colitis we 
observe  may  be  mediated  by  increased  levels  of  IL-12,  which  induces  Th1  cell 
differentiation leading to pathology (Becker et al. 2006; Kullberg et al. 2006). However, 
recently another IL-12 family member, IL-23 was identified (Trinchieri et al. 2003). IL-
23 is composed of the p40 subunit from IL-12 and a p19 subunit. IL-23 has been found 
to  be  important  for  the  expansion  of  precommited  Th17  cells  (Bettelli  et  al.  2006; 
Veldhoen et al. 2006). It is now known that both IL-12 and IL-23 play an important part 
in the immune pathology developing in colitis (Becker et al. 2006; Uhlig et al. 2006; 
Yen  et  al.  2006).  It  has  been  shown  that  IL-23  is  responsible  for  local  intestinal 
inflammation, whereas IL-12 was responsible for the systemic inflammation (Uhlig et 
al. 2006). Uhlig et al. (2006) have shown that IL-12 is important in the development of 
wasting  disease  and  serum  cytokine  production  seen  in  colitis,  whereas,  IL-23  is 
important for the mucosal immunopathology observed. IL-23 is now thought to be the 
main inducer of chronic intestinal inflammation via the induction of both IFN-γ and IL-
17 production (Hue et al. 2006; Kullberg et al. 2006). These cytokines have been shown   150 
to play an important part in the development of spontaneous colitis in various mouse 
models (Kontoyiannis et al. 1999; Kontoyiannis et al. 2002; Uhlig et al. 2006).  
  Although we have no data regarding IL-23 production by macrophages or DC it 
is possible that elevated levels of IL-23 may also play a role in the Tpl-2
-/- x Il-10
-/- mice 
resulting in colitis. As the data shown here are only preliminary, more studies will have 
to be carried out in order to determine the mechanisms leading to the early pathology 
observed in the Tpl-2
-/- x Il-10
-/- mice. This would include increasing the numbers of 
mice to verify the difference in the early development of colitis in the Tpl-2
-/- x Il-10
-/- as 
compared to the Il-10
-/- mice in the same cages to ensure no difference in the gut flora. 
We know from our studies with the Tpl-2 mice that they do not develop colitis 
although in vitro generated macrophages have enhanced IL-12 levels but reduced TNF 
(Figure 5.2.4) (Dumitru et al., 2000 and our data) but as yet we have no data on IL-23. 
Thus it is presently unknown whether singularly Tpl-2 and ERK may play a role in the 
regulation of the immune response and the development of colitis development in the 
presence of particular gut flora. A recent study in the Nf-κb1
-/- mouse shows that after 
challenge with Helicobacter hepaticus increased IL-12p40 is observed. This coincides 
with  deficient  ERK  expression  in  those  mice,  suggesting  that  ERK  may  play  an 
important role in protecting mice from Helicobacter induced colitis through regulation of 
IL-12p40 but this is not observed in “spontaneous” colitis resulting from colonisation by 
gut microflora (Tomczak et al. 2006). Of course though regulation of IL-12p40 any 
effects may be attributable to IL-12 or IL-23, although IL-23 has been attributed with the 
major role in colitis induction, Kullberg et al. (2006) suggest that IFN-γ (hence IL-12) 
may also still play some role.   151 
We do not know as of yet if the colitis observed in the Tpl-2
-/- x Il-10
-/- mice is 
dependent  on  Helicobacter,  as  since  their  arrival  the  mice  have  been  kept  in  the 
quarantine unit for studies. Thus a number of questions rising from our study need to be 
addressed such as: What is the mechanism whereby the Tpl-2
-/- x Il-10
-/- mice develop 
accelerated colitis as compared to the Il-10
-/- mice, which develop the disease later or as 
compared to the Tpl-2
-/- mice, which never develop the disease? Tpl-2
-/- mice show no 
pathology  although  these  mice  have  reduced  but  not  absent  production  of  IL-10  by 
macrophages and DC, but this has not been confirmed in vivo in the gut, which may be 
sufficient to protect them from colitis. 
  As the phenotype of the Tpl-2
-/- x Il-10
-/- mice only became obvious towards the 
end of the thesis, there are still some key experiments outstanding. Originally we bred 
these mice to study the role of Tpl-2 in regulating IL-12 and IFN-β in the complete 
absence of IL-10, however, the Tpl-2
-/- x Il-10
-/- mice developed diarrhoea at around 6 
weeks of age. Breeding a sufficient number of mice for RNA and cytokine experiments 
was not possibly in the time left for completion of this thesis. At this stage, we do not 
have a mechanism for the accelerated gut pathology and experiments will have to be 
repeated with increased numbers of mice as explained earlier. 
  We know that cultured bone marrow-derived macrophages have increased IL-12, 
but decreased TNF in response to LPS and CpG stimulation (Figure 5.2.10), however, 
we as yet have not determined the serum cytokines and the local cytokine production in 
the gut. Based on the factors, which have been implicated in the development of colitis 
and wasting disease measurements of  IL-12p40, IL-12p70, IL-23 and TNF should be 
performed. RNA could from cultured colonic explants also be measured for cytokine   152 
expression as this would help us to get a more complete picture of the cytokine profile of 
the Tpl-2
-/- x Il-10
-/-  mice.  
Finally  if we find elevated levels of IL-12 and/or IL-23 in the colon or serum, 
we would like to treat the Tpl-2
-/- x Il-10
-/- mice with anti-IL-12p40 and anti-IL-23p19 
antibodies in order to determine the cause of the colitis. As this anti-IL-12p40 blocks 
both IL-12p70 and IL-23, it would not be enough to determine whether the onset of 
colitis is mediated by IL-12 or IL-23. Therefore, treatment with IL-23p19 monoclonal 
antibodies are required to answer this question.  
 
6.5.4 The role of regulatory T cells in colitis development. 
 
   CD4
+CD25
+  T-regs  have  been  found  to  be  important  in  maintaining  the 
intestinal  homeostasis  (Hue  et  al.  2006).  It  has  been  shown  that  transfer  of 
CD4
+CD45
high T cells into RAG deficient mice can lead to the development of colitis 
associated with the expansion and accumulation of T cells and DC in the intestine (Hue 
et  al.  2006).  However,  cotransfer  of  CD4
+CD45
high and  T-regs
 into  immunodeficient 
mice can prevent the development of colitis. Moreover, T cell-induced colitis can be 
cured by transfer of T-regs (Izcue et al. 2006). 
We would like to carry out some flow cytometry staining of the bone marrow, 
lymph nodes, spleen and gut to determine whether there are reduced cell numbers of 
CD4
+CD25
+foxP3
+ regulatory T cells. This would have to be compared to the wildtype, 
Tpl-2 and IL-10 deficient mice in order to identify whether there are any differences in 
the cell populations, which could possibly explain the early onset of colitis. Therefore it   153 
is a possibility that the Tpl-2
-/- x Il-10
-/- mice may lack T-regs leading to the early onset 
of colitis.   154 
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 Figure 6.1: Weight chart of mice. Mice were weighed every week to monitor 
weight loss. LM is the littermate wildtype control. Note scales between graphs are 
different.   156 
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Figure 6.2.1: Colons from Tpl-2/IL-10 deficient mice are significantly smaller 
and thicker than littermates. Colons from the 4 phenotypes were removed at 33 
weeks of age and photographed to show differences in size.   157 
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Figure 6.2.2: Colons from Tpl-2/IL-10 deficient mice are shorter and heavier 
than Tpl-2
-/- or IL-10
-/-. Before colons were fixed in formalin they were measured 
and weighed to show size differences. 
P value =0.001   158 
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Figure 6.3: Tpl-2/IL-10 deficient mice show severe colitis. Intestinal samples 
were fixed in formalin and stained with H and E. Magnification 400 times.   159 
 
 
 
 
Chapter 7 
Future perspectives   160 
7.1 Outstanding questions from work in this Ph.D. thesis 
 
7.1.1 Summary of literature regarding questions at the beginning of our study. 
 
How Tpl-2/ERK phosphorylation in DC as well as macrophages affects cytokine 
production. 
 
  The aim of this thesis was to investigate the role of ERK in regulating cytokine 
production in DC and macrophages. We used two different strategies to do this. Firstly 
we  pharmacologically  blocked  ERK  phosphorylation  with  an  inhibitor.  Secondly  we 
used genetically modified mice lacking Tpl-2, which is a MAP kinase that specifically 
activates the ERK signalling pathway. 
There  are  conflicting  reports  whether  it  is  possible  to  induce  ERK 
phosphorylation in TLR stimulated DC and therefore whether phosphorylation of ERK 
regulates cytokine production in DC. Hacker et al. (1999) showed that CpG could not 
induce ERK phosphorylation in myeloid DC but could in macrophages. In contrast to 
this report, Agrawal et al. (2003) and Dillon et al. (2004) have both shown that ERK 
phosphorylation could be induced in human or splenic DC following LPS stimulation 
and led to regulation of IL-12. However, it was unclear in this study whether negative 
regulation of IL-12 by ERK activation was through the induction of IL-10 or by an IL-
10-independent mechanism. 
  In macrophages it had been shown that negative regulation of IL-12 by ERK 
phosphorylation  in  IL-10  deficient  splenocytes  was  not  observed  (Yi  et  al.  2002), 
although the results were difficult to interpret because of a mixed population of cells.   161 
We  set  out  to  clarify  the  reported  differences  by  systematically  examining  direct 
negative effects of ERK phosphorylation on IL-12 induction in the absence of IL-10, a 
known  regulator  of  IL-12  using  pure  populations  of  macrophages  and  myeloid  DC 
stimulated with LPS or CpG.   
 
7.1.2 Summary of data presented in this thesis which answers some of the questions in 
the literature. 
 
CpG as well as LPS leads to ERK phosphorylation in macrophages and DC. 
 
  In  preliminary  experiments  in  this  thesis  we  first  identified  the  optimal 
concentrations  of  LPS  and  CpG  for  activation  of  MAP  kinases  and  induction  of 
cytokines in macrophages and myeloid DC. We also identified the optimal time points 
for activation of MAP kinases and induction of cytokines. We conclusively show that 
both LPS and CpG were able to induce phosphorylation of ERK in macrophages and 
myeloid DC, although Hacker et al. (1999) had reported that CpG could not induce ERK 
phosphorylation in DC, which could potentially be due to the high background in their 
assay. 
 
Tpl-2 activation results in ERK as well as p38 phosphorylation. 
 
  It had been suggested that Tpl-2 exclusively regulates ERK phosphorylation and 
does not affect other MAP kinases (Dumitru et al. 2000). We have now shown that Tpl-  162 
2 not only regulates ERK phosphorylation but also affects p38 phosphorylation. In Tpl-2 
deficient LPS or CpG stimulated macrophages and DC, we show ERK phosphorylation 
is  completely  blocked,  however  we  also  show  that  p38  phosphorylation  is  reduced, 
albeit to a much lesser extent. 
 
TNF is regulated by Tpl-2/ERK to a small extend at the mRNA level. 
 
We  have  confirmed  that  TNF  induction  in  macrophages  and  myeloid  DC  is 
regulated by the Tpl-2/ERK pathway and have shown that TNF is regulated both at the 
induction  of  mRNA  and  protein  level.  This  is in  contrast  to  data  by  Dumitru et  al. 
(2000), who showed that TNF was only regulated post-transcriptionally. The effects of 
Tpl-2/ERK on TNF protein induction can now be explained by studies by Rousseau et 
al. (2008), who show that ERK is required for the phosphorylation of TACE in order to 
induce TNF protein. 
 
ERK activation negatively regulates IL-12 production in the absence of IL-10. 
 
We have also confirmed studies that IL-10 negatively regulates IL-12 production 
(reviewed in Moore et al. 2001), but shown for the first time that IL-12 production is 
also  regulated  negatively  by  the  activation  of  the  ERK  MAP  kinase  pathway  in  the 
complete absence of IL-10, which clarifies previous findings of Pulendran et al. (2003), 
which did not establish whether ERK activation in DC was via IL-10 only or also via an 
IL-10 independent pathway. Our data show that both are the case.   163 
ERK activation leads to negative regulation of IFN-β β β β. 
 
Hacker et al. (2006) have suggested that IL-10 and type I IFN are co-ordinately 
regulated by TRAF3. However, we show that in the absence of ERK activation (U0126 
or Tpl-2 deficient mice) that IFN-β production was enhanced in the absence of ERK 
activation by U0126 or in Tpl-2 deficient cells. As yet we do not know whether the 
increased levels of IFN-β observed are due to the lack of ERK signalling or solely due to 
decreased levels of IL-10 when ERK phosphorylation is abrogated, but our data suggest 
that IL-10 and IFN-β are not co-ordinately regulated.. 
 
Tpl-2
-/- x Il-10
-/- mice develop accelerated colitis as compared to the Il-10
-/- mice. 
 
Finally we found that in the absence of both IL-10 and Tpl-2, mice developed 
colitis within 6-8 weeks of age. The onset of colitis was accelerated compared to IL-10 
deficient mice, which on this genetic background and in our animal facility develop 
colitis at 4-6 months of age (Davidson et al. 1996).   164 
7.2 Outstanding questions resulting from this Ph.D. thesis work 
 
7.2.1  Tpl-2  possibly  affects  other  signalling  pathways  than  the  ERK  MAP  kinase 
pathway.  
 
  We show that stimulation of macrophages or myeloid DC with LPS or CpG in 
the presence of the U0126 MEK inhibitor show decreased TNF induction at both the 
mRNA and protein level as compared to vehicle control. U0126 completely blocked 
ERK phosphorylation in macrophages and DC but however did not completely block 
TNF production. Stimulated macrophages and DC from Tpl-2 deficient mice, which also 
have blocked ERK activation also show a decrease in the TNF level but this inhibition is 
more pronounced than seen with the U0126 inhibitor. This shows that Tpl-2 regulates 
TNF production via ERK and potentially another pathway. One possibility is via p38 
activation as we have shown that Tpl-2 affects phosphorylation of p38. We found that in 
the absence of Tpl-2, p38 phosphorylation was impaired and this could possibly explain 
the  differences  observed  between  the  U0126  MEK  inhibitor  and  the  Tpl-2  deficient 
cells. No differences in JNK phosphorylation were observed in the Tpl-2 deficient mice. 
The  effect  of  Tpl-2  deficiency  on  p38  phosphorylation  was  clearer  in  macrophages 
stimulated with CpG than with LPS stimulation. In myeloid DC stimulated with LPS or 
CpG  the  effect  on  p38  phosphorylation  was  more  pronounced  than  observed  in 
macrophages. These data suggest that subtle differences in MAP kinase activation may 
result from activation of through different TLR ligands and/or intrinsic differences in 
MAP kinase activation in macrophages and DC. Complete blockade of ERK activation   165 
by U0126 with no effects on p38 phosphorylation implies that the p38 defect in the Tpl-
2 deficient mice was not due to inhibition of ERK activation. Thus, Tpl-2 may directly 
regulate MKK3/6 or an as yet unidentified signalling pathway. 
Consistent  with  hypothesis  that  Tpl-2  may  activate  additional  signalling 
pathways other than ERK, IL-12p70 was not detected in macrophages stimulated with 
LPS or CpG in the presence of the U0126 MEK inhibitor, but was detected in Tpl-2 
deficient  macrophages  after  LPS  or  CpG  stimulation.  Since  we  show  that  ERK 
phosphorylation is completely abrogated in the presence of the MEK inhibitor U0126 
and that the addition of U0126 to Tpl-2 deficient macrophages or DC showed little or no 
additional  effect,  these  data  suggest  that  Tpl-2  may  function  via  another  signalling 
pathway to affect IL-12p70. This could be through p38 activation, however Tanaka et al. 
(2002)  have  previously  shown  that  p38  phosphorylation  is  required  for  IL-12p70 
induction. This implies that Tpl-2 negatively regulates IL-12 induction via ERK and 
potentially another pathway. This difference in cytokine levels between cells deficient in 
Tpl-2  or  pharmacological  inhibition  of  ERK  phosphorylation  indicates  that  there  is 
potentially  another  signalling  pathway  controlled  by  Tpl-2,  independent  of  ERK 
activation. Although there is still the possibility that there is still a residual level of ERK 
activation in the presence of the inhibitor, which is absent in Tpl-2 deficient cells.   166 
7.2.2 Signalling in macrophages and DC suggest that they have different levels of ERK 
activation, which may account for different cytokine profiles. 
 
  Stimulation of macrophages with LPS and CpG lead to strong phosphorylation of 
ERK. In myeloid DC, we also detect ERK phosphorylation, which is in contrast to data 
by Hacker et al. (1999), although the signal strength appears weaker than that observed 
in the macrophages, although as yet we have not systematically addressed this. We have 
also detected differences in signal strength for p38 phosphorylation. This could possibly 
indicate that macrophages may show higher levels of ERK and p38 activation. This 
could determine different cytokine profiles observed in macrophages and myeloid DC 
upon stimulation with LPS and CPG. For example, we cannot detect IL-12p70 in the 
macrophages stimulated with LPS or CpG in the presence of U0126, (although IL-12p40 
was detectable) but can in the myeloid DC after U0126 treatment. As IL-12 is negatively 
regulated by ERK, it could be that the lower levels of ERK activation in the myeloid DC 
could account for this difference.  
 
7.2.3 Other potential mechanisms for TNF induction in DC than by Tpl-2 and ERK 
signalling. 
 
  Our data indicates that there are differences in the extent of inhibition of Tnf 
mRNA and TNF protein in macrophages and myeloid DC from the Tpl-2 deficient mice 
after LPS or CpG stimulation. Tpl-2 deficient macrophages fail to induce TNF protein 
upon stimulation with LPS or CpG. On the other hand, myeloid DC from the Tpl-2   167 
deficient  mice  still  produce  significant  TNF  protein  upon  LPS  or  CpG  stimulation, 
although  the  TNF  protein  is  much  decreased  as  compared  to  macrophages  from  the 
littermate controls.  
One possible explanation could be that myeloid DC produce higher amounts of 
TNF  protein  compared  to  the  macrophages  and  therefore,  the  immunoassay  used  to 
measure TNF levels can detect TNF in the Tpl-2 deficient myeloid DC but not in the 
macrophages as they may produce TNF at a level lower that the sensitivity of the assay. 
Another possibility is that TNF can be induced by an additional mechanism to Tpl-
2/ERK signalling in myeloid DC, but not in macrophages.  
The differences observed could also be due to residual ERK activity in the Tpl-2 
deficient DC, although we do not believe this is likely as ERK phosphorylation appears 
to be completely blocked in the Tpl-2 deficient DC and also addition of U0126 MEK 
inhibitor does not decrease TNF production any further in Tpl-2 deficient DC.  
 
7.2.4 IFN-β regulation through IL-10 or ERK activation. 
 
  We have shown that in the absence of ERK activity both by pharmacological 
inhibition of ERK phosphorylation with U0126 and in the Tpl-2 deficient mice, type I 
IFN, IFN-β is increased upon stimulation of macrophages and DC with LPS or CpG. At 
this stage we do not know the mechanism for this increased level of IFN-β. Firstly this 
elevation could result from the decreased levels of IL-10 observed in the absence of 
ERK  phosphorylation  or  it  could  be  regulated  by  the  ERK  signalling  pathway 
independently  of  IL-10.  This  hypothesis  will  need  further  testing  using  the  IL-10   168 
deficient mice in the presence or absence of U0126 or the Tpl-2/IL-10 deficient mice. 
There has been a recent report which suggested that type I IFN and IL-10 were co-
ordinately regulated by TRAF3 (Hacker et al. 2006). However, our data suggests that 
IL-10 and IFN-β regulation can be distinctly regulated via the Tpl-2/ERK signalling 
pathway as in the absence of ERK activation we detect reduced IL-10 but increased 
IFN-β induction both at the mRNA and protein level.  
  To  investigate  the  potential  role  of  IL-10  in  regulating  IFN-β,  in  future 
experiments  IL-10  deficient  macrophages  and  myeloid  DC  will  be  stimulated  in  the 
presence of the MEK inhibitor U0126 and the IFN-β levels will be investigated at both 
the mRNA and protein level. If IFN-β is increased in the IL-10 deficient mice, but no 
further increase is detected upon inhibition of ERK activation, this would indicate that 
IFN-β  is  negatively  regulated  only  by  IL-10  and  not  directly  by  ERK  activation  of 
transcription factors directly regulating IFN-β via an as yet unidentified transcription 
factor in the absence of IL-10. If a further increase is detected upon inhibition of ERK 
activation  in  the  complete  absence  of  IL-10,  this  would  indicate  that  IFN-β  is  also 
negatively regulated by the ERK pathway as seen with IL-12. This will also need to be 
confirmed using the Tpl-2/IL-10 deficient mice. If the Tpl-2/ERK pathway negatively 
regulates IFN-β in the complete absence of IL-10, it will be of interest to determine 
which downstream transcription factors are responsible for this negative regulation of 
IFN-β expression.   169 
7.2.5 Mechanism for induction of colitis in the Tpl-2/IL-10 deficient mice. 
 
  We observed that the Tpl-2/IL-10 deficient mice developed diarrhoea at the age 
of 6-8 weeks as compared to the IL-10 deficient mice, which develops colitis at 4-6 
month of age, indicating that the Tpl-2 deficiency accelerates the onset of colitis. We 
found  that  the  onset  of  diarrhoea  coincided  with  a  reduction  in  weight  gain  and 
eventually weight loss. Preliminary histology showed that the Tpl-2/IL-10 deficient mice 
suffered from premature colitis. As of yet we do not know that exact cause of why these 
mice show accelerated onset of disease as compared to the IL-10 deficient mice.  
We would like to carry out flow cytometry staining of the bone marrow, spleen, 
gut and lymph nodes, in order to determine whether the Tpl-2/IL-10 deficient mice have 
the  same  number  of  CD4
+CD25
+foxP3
+  cells  as  compared  to  the  wildtype,  Tpl-2 
deficient and IL-10 deficient mice. Potentially a lack of these regulatory T cells could 
partly explain the accelerated onset of colitis seen in the Tpl-2/IL-10 deficient mice. T-
regs  have  been  found  to  be  important  in  maintaining  the  intestinal  homeostasis 
(Schmidt-Supprian et al. 2004). It has been shown that transfer of CD4
+CD45
high T cells 
into  RAG  deficient  mice  can  lead  to  the  development  of  colitis  associated  with  the 
expansion and accumulation of T cells and DC in the intestine, however this does not 
occur  if  the  mice  are  kept  under  germ-free  conditions  (Hue  et  al.  2006).  However, 
cotransfer  of  CD4
+CD45
high  and  T-regs
  into  immunodeficient  mice  can  prevent  the 
development of colitis. Moreover, T cell-induced colitis can be cured by transfer of T-
regs (Izcue et al. 2006).    170 
  Initially  we  did  not  expect  these  mice  to  become  ill,  as  from  studies  with 
macrophages  we  found  that  they  have  lower  levels  of  TNF,  which  is  one  of  the 
mediators of colitis. 
 However, we expected them to have higher IL-12 levels possibly in the serum 
and the gut, which was also suggested earlier to be a mediator of colitis. Data using bone 
marrow derived macrophages from the Tpl-2/IL-10 deficient mice show that compared 
to the IL-10 deficient mice, they have lower TNF levels but higher IL-12p40 and IL-
12p70 levels but as yet we have not studied the effects on IL-23, but we would like to 
test this, as recent reports have suggested that IL-23 is required for the chronic intestinal 
pathology observed in colitis (Hue et al. 2006; Kullberg et al. 2006). 
We would like to confirm elevated levels of IL-12 in the serum and gut of the 
mice and we have collected a large number of serum samples ready for processing. We 
hope to be able to identify the cause of the accelerated disease from these samples by 
identifying  which  cytokines  are  elevated  in  the  Tpl-2/IL-10  double  knockout  as 
compared to the Tpl-2 and IL-10 deficient mice and littermate controls. Examination of 
the intestinal cytokines produced in would be in order to pinpoint which cytokines are 
elevated at the early onset of the disease. Samples would have to be collected at various 
time  points  throughout  the  course  of  the  disease  to  allow  a  thorough  analysis  as 
compared to the IL-10 deficient mice, which develop the disease much later.  
If we find as predicted elevated levels of IL-12 or IL-23 in the serum, we would 
like to treat the Tpl-2/IL-10 deficient mice with monoclonal antibodies to IL-12p40 to 
investigate whether this would be enough to block the onset of disease. However as this 
antibody blocks both IL-12p70 and IL-23, it would not be enough to determine whether   171 
the  onset  of  colitis  is  mediated  by  IL-12  or  IL-23.  Therefore,  treatment  with  either  
antibodies to IL-12p70 (p35) or IL-23 (p19) is required to answer this question.  
As  the  mice  have  been  kept  in  a  quarantine  unit  and  not  a  pathogen  free 
environment, we would like to examine screen the mice for helicobacter infections in 
order to determine if this is the cause of the accelerated onset of colitis and see if they 
still develop colitis when they have been rederived into a clean facility. However, it has 
been shown that IL-10 deficient mice on the C75BL/6 background develop colitis upon 
helicobacter infection at 14 weeks (Kullberg et al. 1998; Kullberg et al. 2001). The IL-
10 deficient mice in our unit start showing failure to gain weight around 13 weeks of 
age, but no other clinical signs of colitis, as confirmed by histology. This result could 
potentially rule out a helicobacter infection. 
  Finally, we have also collected the colons from the mice, which will have to be 
processed and scored in order to show the severity of the disease as compared to the IL-
10 deficient mice but this would require larger numbers of mice, particularly since this is 
not an absolute difference in phenotype but rather accelerated colitis in the Tpl-2/IL-10 
deficient mice as compared to the IL-10 deficient mice. This is the scope of future 
studies that will require time in order to collect enough samples for processing.   172 
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